Publicaciones Internacionales del Grupo de Hematología

Nº Publicaciones: 442
FI: 2605,407
FI medio por publicación: 5,89

AÑO 2004
  • Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial.
    Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Schafhausen P, Jost L, Delabarre F, Marcus R. Bone Marrow Transplant .2004, 34(11):955-62
  • Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA, Vicent MG, Gonzalez ME, Verdeguer A, de la Rubia J, Bargay J, de Arriba F, Diez JL, Caballero D, Madero L, Brunet S; Spanish Group for Allogeneic Peripheral Blood Transplantation. Bone Marrow Transplant. 2004 Sep;34(5):433-8
  • Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation.
    Gallardo D, De la Camara R, Torres A, Brunet S, Jimenez A, Vallejo JC, Sanz G, Serrano D, Carreras E, Martin C, Sanz-Rodriguez C, Sierra J, Espigado I, Caballero D, Berlanga JJ. Leukemia. 2004 Jun;18(6):1165-7.
  • Follicular lymphoma international prognostic index.
    Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Blood.2004, 104(5):1258-65
  • Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
    Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, Garcia-Sanz R, Garcia-Larana J, Grande C, Llanos M, Martinez R, Flores E, Mendez M, Ponderos C, Rayon C, Sanchez-Godoy P, Zamora J, Piris MA; Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004 May 1;22(9):1664-73.
  • Chromosomal abnormalities are related to location and grade of osteoarthritis.
    Castellanos MV, Hernandez JM, Ramos L, Belen Gonzalez M, Gutierrez NC, Leone PE, Lumbreras E, Robledo C, Garcia Hernandez JL. Osteoarthritis Cartilage.2004, 12(12):982-5
  • Genetics and Cytogenetics of Multiple Myeloma
    Rafael Fonseca, Bart Barlogie, Regis Bataille, Christian Bastard, P. Leif Bergsagel, Marta Chesi, Faith E. Davies, Johannes Drach, Philip R. Greipp, Ilan R. Kirsch, W. Michael Kuehl, Jesus M. Hernandez, Stephane Minvielle, Linda M. Pilarski, John D. Shaughnessy, Jr., A. Keith Stewart and Herve Avet-Loiseau.. Cancer Research 2004, 64: 1546-1558
  • Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
    Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, Garcia-Sanz R, Garcia-Larana J, Grande C, Llanos M, Martinez R, Flores E, Mendez M, Ponderos C, Rayon C, Sanchez-Godoy P,Zamora J, Piris MA; Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004, 22(9):1664-73
  • Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases.
    Martino R, Salavert M, Parody R, Tomás JF, de la Cámara R, Vázquez L, Jarque I, Prieto E, Sastre JL, Gadea I, Pemán J, Sierra J. Clin Infect Dis. 2004 Feb 1;38(3):335-41.
  • Chromosomal abnormalities are related to location and grade of osteoarthritis
    Castellanos MV, Hernández JM, Ramos L, Gonzalez B, Gutiérrez NC, Leone PE, Lumbreras E, Robledo C, García JL.Osteoarthritis Cartilage 2004;12(12):982-985.
  • Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report.
    R. Fonseca, B. Barlogie, R. Bataille, Ch. Bastard, P.L. Bergsagel, M. Chesi, F.E. Davies, J. Drach, P.R. Greipp, I.R. Kirsch, W.M. Kuehl, J.M. Hernandez, S. Minvielle, L.M. Pilarski, J.D. Shaughnessy, A.K. Stewart, H. Avet-Loiseau. Cancer Res 2004;64:1546-1558.
  • Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma derived cell line. T. Dettori, D.V. Frau, J.L. Garcia, G. Pierantoni, C. Lee, J.M. Hernández, A. Fusco, C.C. Morton, R. Vanni. Cancer Genet Cytogenet 2004;151:171-177.
  • Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia.
    C. Casas, A. Aventín, F. Fuentes, T. Vallespí, I. Granada, I. Carrió, J.A. Martínez-Climent, F. Solé, M teixidó, M Bernues, J Duarte, J.M. Hernández, S. Brunet, M.D. Coll, J. Sierra. Cancer Genet Cytogenet 2004;153:16-25.
  • Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation
    J. A. Pérez-Simón, I. García- Escobar, J. Martínez, L.Vázquez, D. Caballero, C. Cañizo, M.V Mateos, JF.San Miguel Bone Marrow Transplantation 2004, 33 (2):183-7
  • Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma.
    A.Martín, JA Pérez-Simón, MD Caballero, N López, R García-Sanz, L. Vazquez, MC del Cañizo, JF San Miguel.Bone Marrow Transplantation 2004, 33: 579-587
  • Incidence and characteristics of CD4+/HLA DRhi dendritic cell malignancies
    Clara Bueno, Julia Almeida, Paulo Lucio, Josefa Marco, Raimundo García, José María de Pablos, Antonio Parreira, Fernando Ramos, Francisco Ruiz- Cabello, Dimas Suarez- Vilela, Jesús F. San Miguel, Alberto Orfao.Haematologica 2004, 89:58-69
  • The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is more than a gentle approach for relapsed/refractory multiple myeloma providing durable remissions.
    R García- Sanz, J R González-Porras, JM Hernández, M Polo-Zarzuela, A Sureda, C Barrenetxea, L Palomera, R Lopez, C Grande-García, A Alegre, M Vargas-Pabón, O N Gutierrez, JA Rodriguez, J. F. San Miguel. Leukemia 2004, 18: 856-863
  • Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.
    Pablo Menendez, Adelaida Vargas, Clara Bueno, Susana Barrena, María de Santiago, Antonio López, Julia Almeida, Sergio Roa, Jesús F. San Miguel, Alberto Orfao. Leukemia 2004, 18, 491-498
  • Deletion of chromosome band 13q14 as detected by fluorescence in-situ hybridization is a prognostic factor in patients with multiple myeloma receiving allogeneic dose-reduced stem cell transplantation.
    Nicolaus Kröger, Georgia Schilling, Herman Einsele, Peter Liebisch, Avichai Shimoni, Arnon Nagler, José A. Pérez-Simón, Jesús F. San Miguel, Michael Kiehl, Axel Fauser, Rainer Schwerdtfeger, Hannes Weandt, Herbert Gottfried Sayer, Han Myint, Hans Klingemann, Tatjiana Zabelina, Judith Dierlamm, Axel Hinke, Axel Rolf Zander. Blood 2004, 103 (11): 4056-4061
  • FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
    M. Carmen Chillón, Carina Fernández, Ramón García-Sanz, Ana Balanzategui, Fernando Ramos, Javier Fernández-Calvo, Marcos González, Jesús F. San Miguel. The Hematology Journal 2004, 5: 239-246
  • Inmunophenotyping of Acute leukemias and myelodysplastic syndromes.
    Alberto Orfao, Francisco Ortuño, María de Santiago, Antonio López, Jesús F. San Miguel.
    Cytometry (Part A) 2004, 58A: 62-71
  • Immunophenotypic approach to the identification and characterisation of clonal plasma cells from patients with monoclonal gammopathies
    Perez Andres M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, Valet G, Kraan J, Gratama JW, D´Hacourt JL, Merle – Beral H, Lima M, San Miguel JF, Orfao A. for the EWGCCA and the Spanish network on multiple myeloma. Journal of Biological Regulators and homeostatic Agents 2004, 18:392-8
  • Heterogeneity of structural abnormalities on 7q31.3-q34 region in myeloid malignancies.
    M Belén González, Norma C. Gutiérrez, Juan L. García, Eric F.P.M Schoenmakers, Francesc Solé, M José Calasanz, Jesús F. San Miguel, Jesús M. Hernández. Cancer genetic and Cytogenetic, 2004, 150 (2): 136-43
  • Analysis of hematopoietic progeneitor cells in patients with myelodysplastic syndromes according to the cytogenic abnormalities.
    Natalia López-Holgado, Jose Luis Arroyo, Carmen Pata, Eva Villarón, Fermín Sánchez Guijo, Alejandro Martín, Alberto Orfao, Jesús F. San Miguel, Mª Consuelo del Cañizo
    Leukemia Research 2004, 28: 1181-1187
  • Graft vs. Host diseases and Graft vs Myeloma effect after non-myeloablative allogeneic Transplantation
    J.A Pérez- Simón, D. Caballero, M.V Mateos, J.F San-Miguel. Leukemia & Lymphoma 2004, 45 (9):1725-1729
  • Reply from Jose A. Pérez Simón on behalf of authors.Bone Marrow Transplantation 2004, 33: 975-976
  • Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes.
    L. Suarez, MB Vidriales, G. Sanz, A López, MC López-Berges, M de Santiago, L Palomera, T Bernal, ME Pérez de Equiza, J.F. San Miguel, A. Orfao for the Pethema Cooperative Group.
    Leukemia 2004, 18:1311-1313
  • Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: A single-centre sequential-cohort study.
    A.Martín, MD Caballero, JA Pérez-Simón, N. López-Holgado, MV Mateos, M. González , J.F San Miguel. Bone Marrow Transplantation 2004, 34: 675-682
  • Impact of immunophenptype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities.
    J.L. Arroyo, ME Fernández, JM Hernández, A.Orfao, JF. San Miguel , MC del Cañizo. The Hematology Journal. 2004, 5 (3):227-33
  • Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma.
    R. García-Sanz, MI González-Fraile , G. Mateo, J. Hernández, MC López-Berges, N de las Heras, J. Fernández-Calvo, F. Ortega, JA Portero, A. Bárez, J. Galende, A.Orfao, JF San Miguel. International Journal of Cancer 2004 ,112:884-889
  • Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
    Matti Aapro, Jesús San-Miguel. Oncology 2004, 67 (1):17-22
  • The value of fluorescence in situ hibridization (FISH) for detection of 11q in multiple myeloma (MM).
    M. Belén González, Jesús Mª Hernández, Juan L. García, Eva Lumbreras, Mariana Castellanos, José M. Hernández, Javier Fernández-Calvo, Norma C. Gutierrez, Jesús F. San Miguel. Haematologica 2004, 89 (10): 1213-8
  • Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+ dim chronic natural killer cell large granular lymphocytosis.
    Margarida Lima , Juli Almeida, Andrés García Montero, María dos Anjos Teixeira, María Luis Queirós, Ana Helena Santos, Ana Balanzategui, Alexandra Estevinho, María del Carmen Algueró, Paloma Barcena, Sonia Fonseca, María Luís Amorim, Jose Manuel Cabeda, Luciana Pinho, Marcos González, Jesús San Miguel, Benvindo Justica, Alberto Orfao. American Journal of Pathology 2004, 165 (4), 1117-1127
  • Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    M. Pérez-Andrés, J. Almeida, M. Martín-Ayuso, MJ Moro, M.A García-Marcos, I. Moreno, M. Domínguez, J. Galende, N. Heras, MI González, J.F. San Miguel, A. Orfao. Journal of Biological Regulators and Homeostatic Agents 2004, 2: 161-165
  • CD34+ cells from acute myeloid leukemia, myelodysplastic síndromes and normal bone marrow display different apoptosis and drug-resistance associated phenotypes.
    Lilia Suarez, Mª Belén Vidriales, José Garcia-Laraña, Guillermo Sanz, María-José Moreno, Antonio López, Susana Barrena, Rafael Martinez, Mar Tormo, Luis Palomera, Esperanza Lavilla, Mª Consuelo del Cañizo, Alberto Orfao for the Pethema cooperative group. Clinical Cancer Research 2004, 10: 7599-7606
  • Relapse to prior autograft and chronic graft-versus-host disease atre the strongest prognostic factors for outcome of melphalan/fludarabine-based dose–reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kroger N, Perez-Simón JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauster A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF Brand R, Zander AR. Biol Biology of Blood and Marrow Transpl. 2004, 10 (10): 698-708
  • Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy
    de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de la Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P. J Clin Oncol 2004, 22(8): 1404-12
  • Prognostic and biological significance of chromosomal imbalances assessed by 2004, comparative genomic hybridization in multitple myeloma.
    Norma C. Gutierrez, Juan L. García, Jesús Mª Hernández- Rivas, Eva Lumbreras, Mariana Castellanos, Ana Rasillo, Gema Mateo, José Mª Hernández, Sonia Pérez, Alberto Orfao, Jesús F. San Miguel. Blood , 104 (9): 2661-6
  • Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic vs autologous transplantation: results of a prospective study.
    Díez Campelo M, Pérez-Simón J.A, González-Porras JR, García-Cecilia JM, Salinero M, Caballero MD, Cañizo MC, Ocio EM, San Miguel JF. Bone Marrow Transplantation, 34 (8): 8729-38, 2004
  • Bone remodelation markers are useful in the management of monoclonal gammopathies.
    Hernández JM, Suquia B, Queizan JA, Fisac RM, Sánchez JJ, Fernández-Calvo FJ, García-Sanz R, Olivier C, Barez A, Calmuntia MJ, García-Frade J, Portero JA, López R, Aguilera C, Navajo JA, San-Miguel JF. The Hematology Journal 2004, 5 (6): 480-8
  • Randomized comparison of dexamethasone combiend with melphalan versus melphalan prednisone in the treatment of elderly patients with multiple myeloma.
    Hernandez JM, García-Sanz, R, Golvano E, Bladé J, Fernández-Calvo J, Trujillo J, Soler JA, Gardella S, Carbonell F, Mateo G, San Miguel J. British Journal of Hematology, 2004, 127 (2):159-64
  • Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.
    E. Villarón, J. Almeida, N. López-Holgado, M. Alcoceba, LI Sánchez-Abarca, FM Sánchez Guijo, M Alberca, JA Pérez-Simón, JF San Miguel, MC del Cañizo. Haematologica , 2004, 89:1421-1427
  • Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
    M A. Sanz, G Martín, M González, A León, C Rayón, C Rivas, D Colomer, E Amutio, F Capote, G Milone, J de la Serna, J Román, E Barragán, J Bergua, L Escoda, R Parody, S Negri, MJ. Calasanz, and P Bolufer. Blood 2004, 103: 1237-1243.
  • HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease.
    Gallardo D, Brunet S, Torres A, Alonso-Nieto M, Vallejo C, Jimenez A, Gonzalez M, Sanz G, Serrano D, Espigado I, Osorio S, Carreras E, Martiin C, Sanz-Rodriguez C, Sierra J, Zuazu J, Gonzalez-Escribano MF, Gonzalez JR, Roman J, De Oteyza JP, De La Camara R. Transplantation. 2004; 77:1107-10.
  • Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease-a study within the Europe Against Cancer Program.
    van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, Gottardi E, Pallisgaard N, Beillard E, Hop WC, Hoogeveen PG, Gabert J, van Dongen JJ; Europe Against Cancer Program. Leukemia. 2004;18:884-6
  • Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional
    Bolufer P, Colomer D, Gómez MT, Martínez J, González SM, González M, Nomdedeu J, Bellosillo B, Barragán E, Lo-Coco F, Diverio D, Hermosin L, Garcia-Marco J, De Juan MD, Barros F, Romero R, Sanz MA. Laboratory Trial. Clin Chem. 2004; 50:1088-92.
  • Human platelet antigen systems in allogeneic stem cell transplantation. Effect of HPA mismatch in platelet engraftment and graft versus host disease.
    MD García-Malo, J Corral, M González, C Solano, R González-Conejero, MD Caballero, R Pérez, JM Moraleda, V Vicente. Transfusion. 2004; 44: 771-776.
AÑO 2005
  • Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children with Acute Promyelocytic Leukemia: a Multicenter Study by the PETHEMA Group.
    Juan J. Ortega, Luis Madero, Guillermo Martín, Amparo Verdeguer, Purificación García, Ricardo Parody, José Fuster, Antonio Molines, Andrés Novo, Guillermo Debén, Antonia Rodríguez, Eulogio Conde, Javier de la Serna, María J. Allegue, Francisco J. Capote, José D. González, Pascual Bolufer, Marcos González, Miguel A. Sanz. J Clin Oncol 2005; 23:7632-40.
  • Minor histocompatibility antigen HA-8 mismatch and clinical outcome after hla-identical sibling donor allogeneic stem cell transplantation. Perez-Garcia A, De la Camara R, Torres A, Gonzalez M, Jimenez A, Gallardo D. Haematologica. 2005; 90:1723-4.
  • Prognostic factors affecting long-term outcome after stem cell transplantation in hodgkin´s lymphoma autografted after a first relapse.
    Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, García-Conde J, García-Laraña J, Cabrera R, Jarque I, Carrera D, García-Ruiz JC, Pascual MJ, Rifon J, Moraleda JM, Perez-Equiza K, Albo C, Díaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marin J, Mateos MV, Fernández- Ranada JM, Sierra J, Conde E: grupo español de linfomas / trasplante autólogo de médula ósea cooperative group.
    Ann Oncol, 2005, 16(4):625-33
  • Initial evaluation of febrile neutropenic patients: risk quantification
    Vázquez L, García JE.
    Enferm Infecc Microbiol Clin. 2005, Dec;23 Suppl 5:19-23.
  • Prognostic factors affecting long-term outcome after stem cell transplantation in hodgkin´s lymphoma autografted after a first relapse
    Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, García-Conde J, García-Laraña J, Cabrera R, Jarque I, Carrera D, García-Ruiz JC, Pascual MJ, Rifon J, Moraleda JM, Perez-Equiza K, Albo C, Díaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marin J, Mateos MV, Fernández- Ranada JM, Sierra J, Conde E: grupo español de linfomas /trasplante autólogo de médula ósea cooperative group.
    Ann Oncol 2005, 16(4):625-33
  • Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH).
    Diaz MA, Gonzalez-Vicent M, Gonzalez ME, Verdeguer A, Martinez A, Perez- Hurtado M, Badell I, de la Rubia J, Bargay J, de Arriba F, Diez JL, Caballero D, Madero L, Brunet S; Spanish Working Party for Blood and Marrow Transplantation in Children; Spanish Group for Allogeneic Peripheral Blood Transplantation. Bone Marrow Transplant. 2005, 36 (9) :781-5
  • Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C, Gomez V, Tomás JF, Parody R, Sureda A, Sanz G, Cañizo C, Díez JL, Boqué C; CML Subcommittee of the Spanish Group of Hematopoietic Transplantation (Grupo Español de Trasplante Hemopoyética, GETH).
    Bone Marrow Transplant. 2005 Aug;36 (4):301-6.
  • FISH analisys of hematological neoplasias with 1p36 rearrangements allows to define a cluster of 2.5 Mb included in the minimal region deleted in the 1p36 deletion syndrome.
    I Lahortiga,I Vázquez, E Belloni, JP Román, P Gasparini, FJ Novo, I Zudaire, PG Pellici, JM Hernández, MJ Calasanz, MD Odero. Hum Genet 2005;116:476-485.
  • Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial
    J.M. Ribera, A. Oriol, C. Bethencourt, R. Parody, J.M. Hernández-Rivas, M.J. Moreno, E. Potro, M. Tormo, C. Rivas, J. Besalduch, M.Á. Sanz, J.J. Ortega. Haematologica 2005; 90: 1346-56.
  • The marrow cell continuum: stochastic determinism.
    Quesenberry P, Abedi M, Dooner M, Colvin G, Sanchez-Guijo FM, Aliotta J, Pimentel J, Dooner G, Greer D, Demers D, Keaney P, Peterson A, Luo L, Foster B.Folia Histochem Cytobiol. 2005;43(4):187-90. Review.
  • Incomplete DJH rearrangements.
    Gonzalez D, Garcia-Sanz R. Methods Mol Med. 2005;113:165-73.
  • Gene expresion profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.
    Norma C. Gutierrez, Jesús M. Hernández, Ricardo López-Pérez, Isabel Isidro, Belén González, Manuel Delgado, Encarna Fermiñán, Juan L. García, Lourdes Vázquez, Marcos González, Jesús F. San Miguel
    Leukemia 2005, 19:402-409
  • Long-term immune recovery of patients undergoing allogeneic stem cell transplant: a comparison with their respective sibling donors.
    Fermín M. Sánchez-Guijo, Luis-Ignacio Sánchez Abarca, Clara Bueno, Eva Villarón, Natalia López-Holgado, Lourdes Vázquez, Jesús López–Fidalgo, Jose A. Pérez-Simón, M. Dolores Caballero, Mª Consuelo del Cañizo, Alberto Orfao, Jesús F. San Miguel . Bio. Blood Marrow Transplantation 2005, 11:354-361
  • Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long term hematological recovery after autologous bone marrow transplantation for lymphoma.
    Martín A, Pérez-Simón JA, Caballero MD, López -Holgado N, Vázquez L, Cañizo MC, San Miguel JF. Haematologica 2005, 90 (1):78-85
  • Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Lilia Suarez, Mª Belén Vidriales, Mª José Moreno, Antonio López, José García-Laraña, Cristina Pérez-Lopez, Mar Tormo, Esperanza Lavilla, Mª Consuelo López-Berges, María de Santiago, Jesús F. San-Miguel, Alberto Orfao for the Pethema Cooperative Group. Haematologica 2005, 90 (1):54-9
  • Autologous and allogeneic stem cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with ATRA: the European APL group experience.
    S. de Botton, A. Fawaz, S. Chevret, H. Dombret, X. Thomas, M. Sanza, A. Guerci, J. San Miguel, J de la Serna, C. Garo, AM Stoppa, O. Reman, A. Stamatoulas, M. Fey, JY Cahn, JJ Sotto, JH Bourhis, A. Parry, C. Chomienne, L.Degos, P. Fenaux, European APL group. Journal Clinical Oncology, 23 (1):120-6, 2005
  • Efficacy of Rituximab in an aggressive form of multicentric castleman disease associated with immune phenomena.
    Enrique M. Ocio, Fermín M. Sánchez-Guijo, María Díez-Campelo, Cristina Castilla, Oscar J. Blanco, Dolores Caballero, Jesús F. San Miguel. American Journal of Hematology 78: 302-305, 2005
  • Cell cycle analysis of Waldenström´s macroglobulimnemia
    Enrique M.Ocio, Gema Mateo, Belén Vidriales, M. Consuelo López-Berges, Ramón García-Sanz, Jesús M. Hernández, Alberto Orfao, Jesús F. San-Miguel. Clinical Lymphoma 2005, 5 (4): 250-252
  • Immunophenotypic and cytogenetic comparison of Waldenström´s macroglobuliunaemia and marginal zone lymphoma.
    Enrique M. Ocio, Jesús M. Hernández, Gema Mateo, María L. Sánchez, Belén González, Belén Vidriales, Norma C. Gutierrez, Alberto Orfao, Jesús F. San Miguel. Clinical Lymphoma 2005, 5 (4): 241-245
  • Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone martrow microenvironment.
    M. Pérez-Andrés, J. Almeida, M. Martín-ayuso, MJ Moro, G. Martín Núñez, J. Galende, D. Borrego, MJ. Rodríguez, F. Ortega, J. Hernández, I Moreno, M. Dominguez, G. Mateo, JF. San miguel, A.Orfao. For the Spanish Network on multiple myeloma and the Spanish Network of Cancer Research Centers. Leukemia 2005, 19: 449-455
  • Long-term bone marrow culture data are the most powerful predictorof peripheral blood progenitor cell mobilisation in healthy donors.
    Natalia Lopez-Holgado, Carmen Pata, Eva Villarón, Fermín Sánchez- Guijo, Mercedes Alberca, Alejandro Martín, Mercedes Corral, Ignacio Sánchez-Abarca, José Antonio Pérez-Simón, Jesús F. San Miguel, Mª Consuelo del Cañizo.Haematologica/ The Hematology Journal 2005, 90 (3): 353-359
  • Treatment of multiple myeloma in the upfront setting.
    Kenneth Anderson, J. San-Miguel, M.V Mateos, Paul G. Richardson. The American Journal of Oncology Review 2005, 4(6): 11-13
  • Multiple myeloma: combination therapy and autologous stem cell transplantation.
    S. Jagannath, J. San-Miguel, MV Mateos. The American Journal of Oncology Review 2005, 4(6):14-15,
  • Multifunctional role of Erk5 in multiple Myeloma.
    Xonia Carvajal-Vergara, Soraya Tabera, Juan C. Montero, Azucena Esparis-Ogando, Ricardo López-Pérez, Gema Mateo, Norma Gutierrez, Marisa Parmo-Cabañas, Joaquín Teixidó, Jesus San–Miguel, Atanasio Pandiella. Blood 2005, 105(11):4492-4499
  • Postransplant hematopoiesis in patients undergoing sibling allo-SCT reflects that of their respective donors although with a lower functional capacity.
    Fermin Martín Sánchez-Guijo, Luis–Ignacio Sánchez Abarca, Eva Villarón, Natalia López Holgado, Mercedes Alberca, Lourdes Vázquez, José A. Pérez Simón, Jesús Lopez-Fidalgo, Alberto Orfao, María-Dolores Caballero, María-Consuelo del Cañizo, Jesús F. San Miguel
    Experimental Hematology 2005, 33:935-943
  • Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymfoblastic leukemia:impact on the clinical, biological and imunophenotypical disease characteristics.
    D. Primo, MD Tabernero, JJ Pérez, A. Rasillo, JM Sayagués, AB Espinosa, MC López-Berges, R. García-Sanz, NC Gutierrez, JM Hernández, M Romero, CS Osuna, M Giralt, M Barbon, JF San-Miguel, A Orfao. Leukemia 2005, 19: 713-720
  • International Staging System (ISS) for Multiple Myeloma (MM)
    Philip Greipp, Jesus San Miguel, Brian Durie, John J. Crowley, Bart Barlogie, Joan Blade, Mario Boccadoro, Tony Child, Jean-Luc Harousseau, Robert A.Kyle, Juan J. Lahuerta, Heinz Ludwig,Gareth Morgan,Raymond Powles,Kazuyuki Shimizu, Chaim Shustik, Pieter Sonneveld, Patrizia Tosi, Ingemar Turesson, Jan Westin. Journal of Clinical Oncology 2005, 23(15): 3412-3420
  • Bortezomib is an efficient agent in plasma cell leukemias.
    Azucena Esparís-Ogando, Adrián Alegre, Beatriz Aguado, Gema Mateo, Norma Gutiérrez, Joan Bladé, David Schenkein, Atanasio Pandiella, Jesús F. San Miguel. Int. J. Cancer 2005, 114 (4): 665-667
  • Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
    Gema Mateo, Mariana Castellanos, Ana Rasillo, Norma C. Gutierrez, M. Angeles Montalbán, Mª Luisa Martín, Jesús Mª Hernández, Mª Consuelo López-Berges, Laura Montejano, Joan Bladé, Mª Victoria Mateos, Anna Sureda, Javier de la Rubia, Joaquín Díaz-Mediavilla, Atanasio Pandiella, Juan José Lahuerta, Alberto Orfao, Jesús F. San Miguel. Clinical Cancer Research 2005,3661-3667
  • Reduced intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Rodrigo Martino, Jose A. Pérez-simón, Estela Moreno, José M. Queralto, Dolores Caballero, Marivi Mateos, Anna Sureda, Consuelo del Cañizo, Salut Brunet, Javier Briones, Lourdes Vázquez, Ana Clopés, Jesús F. San-Miguel, Jorge Sierra. Biology of Blood and Marrow Transplantation 2005, 11:437-447
  • Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes.
    J.M. Hernandez, C. Castilla, NC Gutierrez, IM Isidro, M Delgado, J de las Rivas, E Fermiñán, JL García, EM Ocio, MC Cañizo, JF San-Miguel. Leukemia 2005, 19: 1088-1091
  • Bortezomib or high –dose dexamethasone for relapsed multiple myeloma
    Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesús San Miguel, Joan Bladé, Mario boccadoro, Jamie Cavenagh, William S. Dalton, Anthony L. Boral, Dixie L Esseltine, Jane B Porter, David Schenkein, and Kenneth Anderson for the Assessment of Proteasome inhibition for Extending Remissions. APEX investigators. The New England Journal of Medicine 2005, 352: 2487-98
  • Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. David González, Marcos González, Ana Balanzategui, Maria E. Sarasquete, Ricardo López-Pérez, M. Carmen Chillón, Ramón García-Sanz, Jesús F. San-Miguel. Haematologica/ The Hematology Journal 2005, 90:906-913
  • Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.Agnes Fütterer, Miguel R. Campanero, Esther Leonardo, Luis M. Criado, Juana M. Flores, Jesús Mª Hernández-Rivas, Jesús San-Miguel, Carlos Martínez-A. Journal of Clinical Investigation 2005, 115 (9) :1-8
  • Analysis of Methylation pattern in Multiple Myeloma. Jesús San Miguel, Ramón García Sanz, Ricardo Lopez Pérez. Acta Haematologica 2005, 114 (1): 23-25
  • First-line therapy in patients with multiple myeloma
    J. San-Miguel, M.V. Mateos. The American Journal of Oncology Review 2005, Vol 4.No3. Supp 1: 1-3
  • Allogeneic transplant with reduced intensity conditioning regimens (RIC) may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q and 17p)
    MD Caballero, J.A García-Marco, R. Martino, M.V. Mateos, JM Ribera, J. Sarra, A. León, G. Sanz, J de la Serna, R Cabrera, M. González, J. Sierra, J.F. San Miguel. Clin. Cancer Res 2005,11(21): 7757-7763
  • Minimal residual diseases monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reactioin and flow cytometry.
    Sarasquete ME, García-Sanz R, González D, Martinez J, Mateo G, Martinez P, Ribera JM, Hernandez JM, Lahuerta JJ, Orfao A, González M, San Miguel JF. Haematologica 2005, 90 (10):1365-72
  • High–dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the intitial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group (PETHEMA)
    Blade J, Rosino L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, ( PETHEMA). Blood 2005,106(12): 3755-9
  • Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Perez-Simón JA, Diez-Cameplo M, Martino R, Brunet S, Urbano A, Caballero MD, de Leon A, Valcarcel D, Carreras E, Del Cañizo MC, López-Hidalgo J, Sierra J, San-Miguel J.F. British Journal of Haematology 2005, 130(3):394-403
  • Prognostic features of multiple myeloma. San Miguel J, García-Sanz R. Best Pract. Res Clin Haematol 2005,18(4): 569-83
  • Hematological, immunophenotypic and cytogenetic characteristics of acute myeloblastic leukaemia with trisonomy 11.Sierra M, Hernández JM, García JL, Gutierrez NC, Perez JJ, Vidriales MB, Ramos F, Hernandez JM, Romero M, Gonzalez MB, Galende J, San Miguel JF.
    Cancer Genet Cytogenet. 2005,160 (1):68-72
  • CD34+ cell dose and outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Diez-Campelo M, Pérez-Simón JA, Ocio EM, Castilla C, González –Porras JR, Sánchez-Guijo FM, Vázquez L, Caballero MD, Cañizo MC, San Miguel JF.Leukemia Lymphoma 2005, 46 (2): 177-83
  • Thalidomide alone or in combination: results in refractory patients. Jesús San Miguel. Haematologica 2005,1(11): 2-6
  • Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin b.Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF. Haematologica 2005, 90(12)
  • Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Graham Jackson, Hermann Einsele, Phillippe Moreau, Jesús San Miguel. Cancer treatment reviews, 2005, 31: 591- 602
AÑO 2006
  • Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Primo D, Sanchez ML, Espinosa AB, Tabernero MD, Rasillo A, Sayagues JM, Gonzalez M, Hernandez JM, Orfao A. Br J Haematol. 2006; 132:736-9.
  • Impact of bcr/abl gene expression on the proliferative rate of different subpopulations of hematopoietic cells in chronic myeloid leukaemia.Daniel Primo, Juan Flores, Sandra Quijano, María Luz Sanchez, María Eugenia Sarasquete, Javier del Pino-Montes, Per Ivar Gaarder, M González, and Alberto Orfao. Br J Haematol. 2006; 135:43-51.
  • Short tandem repeat markers in diagnostics: what's in a repeat?. M G J Tilanus on behalf of the Eurochimerism Consortium.Leukemia, 2006; 20: 1353-1355.
  • The RSD code: proposal for a nomenclature of allelic configurations in STR-PCR-based chimerism testing after allogeneic stem cell transplantation. F Watzinger, T Lion and C Steward on behalf of the Eurochimerism consortium. Leukemia, 2006; 20: 1448-1452
  • Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H. Blood. 2006 Nov 1;108(9):2928-36.
  • Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R, Martino R, Rovira M, Vazquez L, Vázquez MJ, de la Cámara R, Blazquez C, Fernández-Avilés F, Carreras E, Salavert M, Jarque I, Martín C, Martínez F, López J, Torres A, Sierra J, Sanz GF; Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH). Biol Blood Marrow Transplant. 2006 Jul;12(7):734-48.
  • G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+.Talarn C, Urbano-Ispizua A, Martino R, Batlle M, Fernandez-Aviles F, Herrera C, Perez-Simon JA, Gaya A, Aymerich M, Petriz J, Marin P, Sierra J, Montserrat E. Bone Marrow Transplant. 2006 May; 37(9):873-9.
  • Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Blade J. Clin Lymphoma Myeloma. 2006 Mar; 6(5):380-3.
  • Thalidomide in multiple myeloma.Garcia-Sanz R. Expert Opin Pharmacother. 2006 Feb; 7(2):195-213.
  • Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ.Blood. 2006 May 1;107(9):3442-6.
  • Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E; Programa para el Estudio y Tratamiento de Hemopatias Malignas Group. Cancer. 2006 Jun 15;106(12):2540-6.
  • Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernandez-Calvo J, Orts M, Novo A, Rivas C, Hernandez-Rivas JM, Feliu E, Ortega JJ. Med Clin (Barc). 2006 Jan 21;126(2):41-6. Spanish.
  • The expression of PRDI-BF1beta isoform in multiple myeloma plasma cells. Ocana E, Gonzalez- Garcia I, Gutierrez NC, Mora-Lopez F, Brieva JA, Campos- Caro A. Haematologica. 2006 Oct 17: 1579-80
  • Homocysteine and outcome in young patients with acute coronary syndromes. Martin-Herrero F, Martin-Moreiras J, Pabon P, Sanchez PL, Morinigo-Munoz JL, Jimenez-Candil J, Cruz-Gonzalez I, Alberca I, Gonzalez-Porras JR, Martin-Luengo C.Int J Cardiol. 2006 Oct 2;183-188
  • A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis
    Corral J, Gonzalez-Conejero R, Soria JM, Gonzalez-Porras JR, Perez-Ceballos E, Lecumberri R, Roldan V, Souto JC, Minano A, Hernandez-Espinosa D, Alberca I, Fontcuberta J, Vicente V.
    Blood. 2006 Jul 1;108(1):177-83
  • Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol.
    Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, Garcia-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Diez JL, Moraleda JM, Rubio-Felix D, Xicoy B, Martinez C, Mateos MV, Sierra J.
    Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83.
  • Treatment options in relapsed or refractory Hodgkin disease patients: the mini- BEAM regimen does exist too.
    Canales MA, Martin A, Caballero D, Hernandez-Navarro F.
    Br J Haematol. 2006 Sep;134 (6):645-6.
  • Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source.
    Gallardo D, Perez-Garcia A, de la Camara R, Iriondo A, Jimenez-Velasco A, Torres A, Brunet S, Urbano-Ispizua A, Vallejo C, Encuentra M, Caballero D, Espigado I, Serrano D, Barrenetxea C, Ribera JM, de la Rubia J; Allogeneic Peripheral Blood Transplantation Sub-committee of Spanish Group of Hematopoietic Stem Cell Transplantation (GETH: Grupo Espanol de Trasplante Hemopoyetico).
    Leukemia. 2006 Aug; 20(8):1461-4.
  • Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M, Gallur L, Giraldo P, Hernandez R, Menor D, Rodriguez MJ, Caballero D, Gonzalez R, Mayans J, Millan I, Cabrera JR; On behalf of the Multi-institutional Retrospective Spanish Study on the use of rituximab in refractory ITP.
    Ann Hematol. 2006 Jun; 85(6):400-6.
  • Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R, Martino R, Rovira M, Vazquez L, Vazquez MJ, de la Camara R, Blazquez C, Fernandez-Aviles F, Carreras E, Salavert M, Jarque I, Martin C, Martinez F, Lopez J, Torres A, Sierra J, Sanz GF; Infectious/Non-infectious Complications Subcommittee of the Grupo Espanol de Trasplante Hematopoyetico (GETH).
    Biol Blood Marrow Transplant. 2006 Jul;12(7):734-48
  • Impact of the intensity of the pre-transplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the european group for blood and marrow transplantation. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, Lopez-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H. Blood. 2006, 108(9): 2928-2936
  • Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation
    Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, Arcos MJ, Encinas C, Graciani IF, Ocio EM, Sanchez-Guijo FM, Caballero MD
    Bone Marrow transplantation 2006, 38(12):821-2
  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies report of the Biomed-2 concerted Action BHM4 CT98-3936
    Brugeemann M, White H, Gaulard P, García-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ.
    Leukemia 2006, 21(2):215-21
  • Autologous skeletal myoblast transplantation in patients with nonacute myocardial infaction; 1-year follow-up.
    Gavira JJ, Herreros J, Perez A, Garcia-Velloso ML, Barba J, Martin Herrero F, Cañizo C, Martin –Arnau A, Martin Climent JM, Hernandez M, Lopez-Holgado N, Gonzalez-Santos JM, Martin Luengo C, Alegria E, Prosper F.
    J. Thorac Cardiovasc surg 2006, 131 (4): 799-804
  • Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia.
    Carreras E, Jimenez M, Gomez-garcía V, de la Camara R, Martin Martinez F, Iriondo A, Sanz G, Cañizo C, Cabrera R, Sierra J, Vallejo C, Lopez J, Martinez C, Rovira M, Fernandez-Ranada JM, Torres A.
    Bone Marrow Transplant 2006, 37(1):33-40
  • Diagnosis of hematological malignancies: new applications for flow cytometry.
    Orfao A, Lopez A, Flores J, Almeida J, Vidriales B, Perez J, Kneba M, Macintyre E, Parreira A, Richards S, Szczepanski T, Trka T, Van der Velden VHJ, Van Dongen JJM. Hematology- The hematology association education program 2006; 2 (1):6-13.
  • Analysis of chromosomal imbalances in an elderly woman with a giant cell tumour Garcia JL, Robledo C, Lumbreras E, Flores T, Ramos L, Hernandez JM.. Virchows Arch. 2006; 448: 95-9.
  • Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutierrez-Berzal J, Castellano E, Martin-Encabo S, Gutierrez-Cianca N, Hernandez JM, Santos E, Guerrero C. Exp Cell Res. 2006; 312:938-48.
  • Characterization of a recurrent translocation t(2;3) (p15-22;q26) occurring in acute myeloid leukaemia.
    Trubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, Ciambelli F, Magro D, Hernandez JM, Mancini M, Diverio D, Pelicci PG, Coco FL, Mecucci C, Specchia G, Rocchi M, Liso V, Castoldi G, Cuneo A. Leukemia. 2006; 20: 48-54.
  • Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia.
    Cavazzini F, Bardi A, Tammiso E, Ciccone M, Russo-Rossi A, Divona D, Lo Coco F, Hernandez JM, Wlodarska I, Hagemeijer A, Castoldi G, Cuneo A. Haematologica. 2006; 91: 381-5.
  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.
    Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ. Leukemia. 2007 Feb;21(2):215-21.
  • Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
    M. Bendandi, M. Rodriguez-Calvillo, S. Inogés, A. López-Díaz de Cerio, JA. Pérez-Simón, A. Rodriguez-Caballero, A. García-Montero, J. Almeida, N. Zabalegui, P. Guiraldo, J. San-Miguel, A. Orfao.
    Leukemia & Lymphoma 2006, 47 (1):29-37
  • A practical update on the use of bortezomib in the management of multiple myeloma.
    J. San Miguel, J. Bladé, M. Boccadoro, J. Cavenagh, A. Glasmacher, S. Jagannath, S. Lonial, R. Orlowski, P. Sonneveld, H. Ludwig.
    The Oncologist 2006, 11:51-61
  • TCRγδ+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRγδ+ T-cells
    Y. Sandberg, J. Almeida, M. González, M. Lima, P. Bárcena, t. Szczepañski, Ej van Gastel-Mol, H Wind, A. Balanzategui , JJM van Dongen, J.F. San Miguel , A. Orfao, and AW Langerak.
    Leukemia 2006, 20: 505-513
  • Risk of recurrent venous thromobis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    José- Ramón González- Porras, Ramón García-Sanz, Ignacio Alberca, María Luz López, Ana Balanzategui, Oliver Gutierrez, Francisco Lozano, Jesús San Miguel
    Blood Coagulation and Fibrinolysis 2006, 17: 23-28
  • Bone Marrow mesenchymal stem cells chimerism after allogenic hematopoietic transplantation.
    Villarón E.N, Pérez-Simón JA, San Miguel JF, Del Cañizo C.
    Exp Hematol. 2006, 34(1): 7
  • Characterization of Bone Marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demostrates increased infiltration by cytotoxic /Th1 T cells demonstrating a squed TCR-Vβ repertorie.
    Martín Perez-Andres, Julia Almeida, Marta Martín-Ayuso, Mª Jesús Moro, Guillermo Matín Nuñez, Josefina Galende, José Hernández, Gema Mateo, Jesús San Miguel, Alberto Orfao for the Spanish Network on multiple Myeloma (G03/136) and the Spanish Network of Cancer Research Centers (C03/10).
    Cancer 2006, 106(6): 1296- 1305
  • Remarkable activity of novel agents bortezomib and thalidomide in patients non responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
    Niels W.C J van de Donk, Nicolaus Kröger, Ute Hegenbart, Paolo Corradini, Jesús F. San Miguel, Hartmut Goldschmidt, Jose A. Pérez-Simón, Mark Zijlmans, Reinier A. Raymakers, Vittorio Montefusco, Francis A. Ayuk, Marinus H.J van Oers, Arnon Nagler, Leo F. Verdonck, Henk M. Lokhorst.
    Blood 2006, 107 (8): 3415-3416
  • Chronic Graft-versus-host disease. Pathogenesis and Clinical management.
    José A. Pérez-Simón, Ignacio Sánchez-Abarca, María Diez-Campelo, Dolores Caballero, Jesús San-Miguel
    Drugs 2006, 66(8):1041-57
  • Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
    Blanco B, Perez-Simón JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos-Mazon J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villaron E, Schenkein D, Pandiella A, San Miguel JF.
    Blood 2006, 107(9): 3575-83
  • Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
    Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás J.F, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosinol L, Lahuerta J, Diez-Martín JL, Leon A, García A, Vazquez L, Sierra J, San Miguel JF
    Leukemia 2006, 20: 542-545
  • Oral Beclomtethasone dipropionate for the treatment of gastrointestinal acute graft – versus -host disease (GVHD).
    C. Castilla, J.A Pérez-Simón, F.M Sánchez- Guijo, M. Díez-Campelo, E. Ocio, E. Pérez-Persona, O. López-Villar, L. Vázquez, D. Caballero, J.F. San Miguel.
    Biology of Blood and Marrow Transplantation 2006, 12 (9): 936-41
  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study.
    María-Victoria Mateos, José M. Hernández, Miguel T Hernández, Norma C. Gutierrez, Luis Palomera, Marta fuertes, Joaquín Diáz-Mediavilla, Juan J. Lahuerta, Javier de la Rubia, María-José Terol, Ana Sureda, Joan Bargay, Paz Ribas, Felipe de Arriba, Adrián Alegre, Albert Oriol, Dolores Carrera, José García- Laraña, Ramón García-Sanz, Joan Bladé, Felipe Prósper, Gema Mateo, Dixie-Lee Esseltine, Helgi van de Velde, Jesús F. San-Miguel
    Blood 2006, 108(7): 2165-2172
  • The Histone Deacetylase inhibitor LBH589 is a potents antimyeloma agent that overcomes drug resisteance.
    Patricia Maiso, Xonia Carvajal-Vergara, Enrique M. Ocio, Ricardo López- Pérez, Gema Mateo, Norma Gutierrez, Peter Atadja, Atanasio Pandiella, Jesús San Miguel
    Cancer Res 2006, 66 (11): 5781-5789
  • Efficacy of Darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies.
    Timothy J. Littlewood, Joel D. Kallich, Jesús San Miguel, Lisa Hendricks, Michael Hedenus
    Journal of Pain and Symptom Management 2006, 31(4): 317-325
  • Conventional diagnostics in multiple myeloma.
    Jesús F. San Miguel, Norma C Gutierrez, Gema Mateo, Alberto Orfao.
    European Journal of Cancer 2006, 42: 1510-1519
  • The HDAC inhibitor LBH589 is a potent anti-myeloma agent that overcomes drug resistance.
    Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF
    Clinical Cancer Research 2006, 66(11): 5781-9
  • Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain
    Sierra M, Alonso A, Odero MD, Gonzalez MB, Lahortiga I, Perez JJ, Garcia JL, Gutierrez NC, Calasanz MJ, San Miguel JF, Hernandez JM.
    Leuk Res.2006, 30: 943-948
  • Perspective on the current use of Bortezomib in the treatment of multiple myeloma.
    Jesús San Miguel, Joan Bladé
    Haematologica 2006, 901 (7): 871-872
  • International uniform response criteria for multiple myeloma
    Brian G. Durie, Jean Luc Harousseau, Jesús San Miguel, Joan Bladé, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksac, J. Crowley, A. Belch, M. Boccadoro, I. Turesson, D. Joshua, D. Vesole, R. Kyle, R. Alexanian, G. Tricot, M. Attal, G. Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, G. Morgan and S. Vincent Rajkumar on behalf of the international myeloma working group.
    Leukemia 2006, 20(9): 1467-73
  • Application of self–quenched JH consensus primers for real–time quantitative PCR of IGH Gene to minimal residual disease evaluation in multiple myeloma.
    Joaquín Martinez-López, Pilar Martinerz-Sánchez, Ramón García-Sanz, M. Eugenia Sarasquete, Rosa Ayala, Marcos González, Jesús San Miguel, Guillermo García-Effron and Juan José Lahuerta.
    Journal of Molecular Diagnostics 2006, 8(3): 364-370
  • Prognostic factors for donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
    Niels WCJ van de Donk, Nicoulaus Kröger, Ute Hegenbart, Paolo Corradini, Jesús San Miguel, Harmut Goldschmidt, José A. Pérez-Simón, Mark Zijilmans, Reinier A. Raymakers, vittorio Montefusco, Francis A. Ayuk, Marinus H. J van Oers, Arnon Nagler, Leo F. Verdonck and Henk M. Lokhorst.
    Bone Marrow Transplantation 2006, 37 (12): 1135-41
  • Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. Prieto-Sánchez RM, Hernandez JA, García JL, Gutierrez NC, San Miguel J, Bustelo XR, Hernandez JM. British Journal of Hematology 2006, 133 (6): 642,5
  • Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with mutliple myeloma. Results of the Spanish Myeloma Group (GEM study).
    Javier de la Rubia, Joan Bladé, Juan-José Lahuerta, Jose M. Ribera, Rafael Martinez, Adrian Alegre, José García-Laraña, Pascual Fernández, Anna Sureda, Felipe de Arriba, Dolores Carrera, Joan Besalduch, R. García, Luis Palomera, MT Hernández, Paz Rivas, Javier Pérez-Calvo, Antonio Alcalá, F. Casado, Jesús San Miguel
    Haematologica 2006, 91(5): 621-7
  • Medium term results of percutaneous vertebroplasty in multiple myeloma.
    Ramos L, de las Heras JA, Sanchez S, Gonzalez-Porras JR, González R, Mateos M.V, San Miguel JF,
    European Journal of Haematology 2006, 77(1): 7-13
  • Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a singe tumor cell clone.
    Sanchez ML, Almeida J, Lopez A, Sayagues JM, Rasillo A, Sarasquete EA, Balanzategui A, Tabernero MD, Diaz Mediavilla J, Barranchina C, Paiva A, Gonzalez M, San Miguel JF, Alberto Orfao
    Haematologica 2006, 91(3): 331-9
  • Reduced- intensity conditioning allogenic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
    Perez-Simón JA, Sureda A, Fernandez-Avilés F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF , Moraleda JM, Alegre A, Cañizo C, Breunet S, Rosinol L, Lahuerta J, Diez-Martin JL, León A, García A, Vázquez L, Sierra J, San Miguel J, Grupo español de Mieloma.
    Leukemia 2006, 20(3): 542-6
  • Vincristine is an effective therapeutic approach for transplantation associated thrombotic microangiopathy.
    Mateos J, Perez Simón, JA, Caballero D, Castilla C, López O, Pérez E, Cañizo C, Vazquez L, San Miguel JF.
    Bone Marrow Transplantation 2006, 37 (3): 337-8
  • Pegylated liposomal doxorubicin, melphaln and prednisone therapy for elderely patients with multiple myeloma
    R. García-Sanz, JM Hernández, A. Sureda, J. García-Laraña, F. Prosper, A. Alegre, A. Bérez, MV Mateos, JF. San Miguel
    Hematological Oncology 2006, 24 (4): 205-11
  • The association of increased p14ARF / p6 INK4a and p15INK4b gene expression with proliferative activity and the clinical course of multiple myeloma.
    María Eugenia Sarasquete, Ramón García-Sanz, Adriana Armellini, Marta Fuentes, Patricia Martín- Jiménez, Magdalena Sierra, Maria del Carmen Chillón, Miguel Alcoceba, Ana Balalnzategui, Fernando Ortega, José Mariano Hernández, Anna Sureda, Luis Palomera, Marcos González, Jesús Fernando San Miguel
    Haematologica 2006, 91(11): 1553-1556
  • Prognostic impact of pretransplantation computed tomography and gallium scans in patients with Hodgkin lymphoma with poor prognosis undergoing hematopoietic stem cell transplantation.
    Escobar IG, Barrigon DC, Tamayo P, Pérez-Simón JA, Mateos MV, Garcia JR, San Miguel JF
    Clin Lymphoma Myeloma 2006, 7(3):2117-25
  • Novel drugs for multiple myeloma
    J.F. San Miguel, M.V. Mateos, A. Pandiella
    Hematology ( EHA Educ Program) 2006, 2:205-211
AÑO 2007
  • Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. J Esteve, L Escoda, G Martín, V Rubio, J Díaz-Mediavilla, M González, C Rivas, C Álvarez, J D González San Miguel, S Brunet, J F Tomás, M Tormo, M J Sayas, P Sánchez Godoy, D Colomer, P Bolufer and M A Sanz on behalf of the Spanish Cooperative Group PETHEMA .Leukemia. 2007; 21:446-52
  • Antithrombin Cambridge II (A384S): an underestimated genetic risk factor
    for venous thrombosis. Javier Corral, David Hernandez-Espinosa, Jose Manual Soria, Rocio Gonzalez-Conejero, Adriana Ordonez, Jose Ramon Gonzalez-Porras, Elena Perez-Ceballos, Ramon Lecumberri, Ignacio Sanchez, Vanessa Roldan, Jose Mateo, Antonia Minano, Marcos González, Ignacio Alberca, Jordi Fontcuberta, and Vicente Vicente. Blood 2007; 109:4258-63.
  • Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies V M Guillem, M Collado, M J Terol, M J Calasanz, J Esteve, M Gonzalez, C Sanzo, J Nomdedeu, P Bolufer, A Lluch, M Tormo. Leukemia, 2007, 21:1413-22
  • Monoclonal TCR-V{beta}13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin.Garrido P, Ruiz-Cabello F, Barcena P, Sandberg Y, Canton J, Lima M, Balanzategui A, Gonzalez M, Lopez-Nevot MA, Langerak AW, Garcia-Montero AC, Almeida J, Orfao A. Blood. 2007, 109:4890-98.
  • CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Arianne Pérez-García, Rafael De la Cámara, Jose Román-Gómez, Antonio Jiménez-Velasco, Maite Encuentra, Jose B. Nieto, Javier de la Rubia, Alvaro Urbano-Ispizúa, Salut Brunet, Arturo Iriondo, Marcos González, David Serrano, Ildefonso Espigado, Carlos Solano, Josep M. Ribera, Josep M. Pujal, Montserrat Hoyos, David Gallardo. Blood 2007; 110:461-467.
  • Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real time amplification assays: towards new standards for gene expression measurements Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S, Cayuela JM, Cazzaniga G, Gonzalez M, Grimwade D, Kairisto V, Miyamura K, Lawler M, Lion T, Macintyre E, Mahon FX, Muller MC, Ostergaard M, Pfeifer H, Saglio G, Sawyers C, Spinelli O, van der Velden VH, Wang JQ, Zoi K, Patel V, Phillips P, Matejtschuk P, Gabert J.. Leukemia 2007; 21:1481-1487.
  • Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Rodríguez A, Villuendas R, Yáñez L, Gómez ME, Díaz R, Pollán M, Hernández N, de la Cueva P, Marín MC, Swat A, Ruiz E, Cuadrado MA, Conde E, Lombardía L, Cifuentes F, Gonzalez M, García-Marco JA, Piris MA.. Leukemia. 2007; 21:1984-91.
  • Nephrotic syndrome resulting from focal segmental glomerulosclerosis in a peripheral blood stem cell transplant patient.
    Heras M, Saiz A, Sánchez R, Fernandez-Reyes MJ, Mampaso F, Queizán JA, Molina A, Vázquez L, Alvarez-Ude F.
    J Nephrol. 2007, 20(4):495-8.
  • Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Rodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, Garcia JC, Fernandez P, Canigral G, Bergua J, Caballero MD; Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea. Eur J Haematol. 2007; 78(4):290-6 2,163
  • Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
    Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, Bendandi M, Albo C, Caballero MD; 'Grupo Espanol de Linfomas / Trasplante Autologo de Medula Osea' (GEL-TAMO) . Eur J Haematol. 2007 Jul;79(1):32-8. 2,163
  • The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernandez de Sevilla A, Bendandi M, Solano C, Leon A, Varela MR, Caballero MD; Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group. Haematologica. 2007; 92:1067-74.
  • Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J, Caballero MD, De Mattos SF, Gines J, Martínez J, Lopez A. Leuk Lymphoma. 2007;48(11):2172-8.
  • Peripheral endothelial progenitor cells (CD133 +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cañizo MC, Lozano F, González-Porras JR, Barros M, López-Holgado N, Briz E, Sánchez-Guijo FM. Cytotherapy. 2007; 9 (1):99-102.
  • Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Aliotta JM, Sanchez-Guijo FM, Dooner GJ, Johnson KW, Dooner MS, Greer KA, Greer D, Pimentel J, Kolankiewicz LM, Puente N, Faradyan S, Ferland P, Bearer EL, Passero MA, Adedi M, Colvin GA, Quesenberry PJ.
    Stem Cells. 2007;25(9):2245-56.
  • Launching a clinical program of stem cell therapy for cardiovascular repair. Sánchez PL, Sánchez-Guijo FM, Villa A, del Cañizo C, Arnold R, San Román JA, Fernández-Avilés F.
    Nat Clin Pract Cardiovasc Med. 2007 Feb;4 Suppl 1:S123-9. Review.
  • Stem cell continuum: directed differentiation hotspots. Colvin GA, Dooner MS, Dooner GJ, Sanchez-Guijo FM, Demers DA, Abedi M, Ramanathan M, Chung S, Pascual S, Quesenberry PJ.
    Exp Hematol. 2007 Jan;35(1):96-107.
  • Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. Valcárcel D, Martino R, Caballero D, Martín J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vázquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol. 2007 , 26(4):577-84
  • Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Talarn C, Urbano-Ispizua A, Martino R, Pérez-Simón JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernández-Avilés F, Aymerich M, Marín P, Sierra J, Montserrat E. Haematologica. 2007 ; 92(12):1655-63.
  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.
    Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Leukemia. 2007;21(2):215-21.
  • Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A, Caballero D, Sierra J, Ribera JM, Díez JL.
    Biol Blood Marrow Transplant. 2007 Jun;13(6):701-6.
  • Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E; PETHEMA Group.
    Eur J Haematol. 2007;78(2):102-10.
  • In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions
    Aouacheria A, Navratil V, López-Pérez R, Gutiérrez NC, Churkin A, Barash D, Mouchiroud D, Gautier C.
    BMC Genomics. 2007 Jan 3; 8:2
  • Dose- escalated chop and tailored intensification with IFE according to early response and followed by BEAM/ Autologous stem cell transplantation in poor risk aggressive B cell lymphoma: a prospective study from the GEL-TAMO study group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; On behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO).
    Eur J Haematol. 2007 Dec 18; 227-35
  • Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N.
    J Clin Oncol. 2007 Dec 17; 455-62
  • High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N.
    J Clin Oncol. 2007, 26(2):218-24
  • Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S; UK and Spanish Collaborative Groups.
    Br J Haematol. 2007;139(1):70-80.
  • A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
    Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, Facon T, Fanin R, Caballero D, Ben-Yehuda D, Giles F.
    Leuk Lymphoma. 2007;48(1):39-45.
  • Homocysteine and outcome in young patients with acute coronary syndromes. Martín-Herrero F, Martín-Moreiras J, Pabón P, Sánchez PL, Moríñigo-Muñoz JL, Jimenez-Candil J, Cruz-González I, Alberca I, González-Porras JR, Martín-Luengo C. Int J Cardiol. 2007;118:183-8.
  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.
    Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ. Leukemia. 2007 Feb; 21(2):215-21.
  • Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation : t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a uniqye abnormality is not associated with adverse prognosis
    Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, Carrera D, Rosinol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernandez-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF.
    Leukemia 2007, 21 (1):143-50
  • Functional class switch recombination may occur “in vivo” in Waldenstrom macroglobulinemia.
    Martin-Jimenez P, García-Sanz R, Sarasquete ME, Ocio E, Perez JJ, González M, San Miguel JF.
    Br J. Haematology 2007, 136(1): 114-6
  • 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis.
    Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez- Rivas JM, Gutierrrez NC, García-Sanz R, Moro MJ, Aguilera C, Hernandez J, Xu R, Greipp PR, Dispenzieri A, Jalal SM, Lacy MQ, Gonzalez- Paz N, Gertz MA, San Miguel JF, Fonseca R.
    Br. J. Haematology 2007, 136 (1): 80-6
  • Gene expression profiling of B lymphocytes and plasma cells from Waldenström´s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
    NC Gutierrez , EM Ocio, J. de la Rivas, P. Maiso, M. Delgado, E. Fermiñán, MJ Arcos, ML Sánchez, JM Hernández and JF San Miguel.
    Leukemia 2007, 21 (3):541-82
  • Pemetrexed acts as an anti-myeloma agent by provoking cell cycle blockade and apoptosis
    Jean-Marie Ramirez, Enrique Ocio, Jesús San Miguel, Atanasio Pandiella
    Leukemia 2007, 21 (49): 797-804
  • Management of multiple myeloma with Bortezomib: experts review the data and debate the issues.
    Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.
    Oncology 2007, 70(6):474-482
  • Using quantification of the pml-rarALPHA transcript to stratify the risk of relapse in patients with acute promyelocytic leukaemia.
    C. Santamaria, M.Carmen Chillón, C. Fernández, P. Martín-Jiménez, Ana Balanzategui, Ramón García-Sanz, Jesús F. San-Miguel, Marcos González-Díaz
    Haematologica/ THJ , 2007 , 92 (3):315-22
  • Relapse-risk stratification in acute promyelocytic leukaemia patients by PML-RAR alpha transcript quantification.
    C. Santamaría, MC Chillón, C. Fernández, P. Martín-Jiménez, A. Balanzategui, R. García-Sanz, J. F. San-Miguel, M. González-Díaz
    Haematologica/ THJ , 2007, 92(3): 289-91
  • Safety and efficacy of bortezomib in high –risk and elderly patients with relapsed multiple myeloma
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben –Yekuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC
    Br J Haematology 2007, 137 (5):429-35
  • Short –term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers.
    N. López-Holgado, M. Alberca, F. Sánchez-Guijo, E. Villarón, J. Almeida, A. Martín, A. Armellini, C. García, B. Blanco, I. Sánchez-Abarca, S. Martín, JA Pérez-Simón, R. García-Sanz, J.F San-Miguel and MC del Cañizo
    Cytotherapy 2007, 9 (1): 14-22
  • Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism.
    Gonzalez-Porras JR, Martín-Herrero F, García-Sanz R, Lopez ML, Balanzategui A, Mateos MV, Pavon P, Gonzalez M, Alberca I, San Miguel JF.
    Thromb Res. 2007, 119(6):691-8
  • Molecular characterization of heavy chain immunoglobulin gene rearrangements in waldenstrom´s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Martin-Jimenez P, García-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sánchez ML, González M, San Miguel J
    Haematologica 2007, 92(5):653-42
  • The emerging role of targeted therapy for hematologic malignancies:update on bortezomib and tipifarnib
    Armand JP, Burnett A.K, Drach J, Harousseau JL, Lowenberg B, San Miguel J
    Oncologist 2007, 12(3):281-90
  • New criteria to identify risk of progression in monoclonal gammopathy uncertain significance ans smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Perez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, García de Coca A, Galende J, Martín –Nunez G. Alonso JM, de las Heras N, Hernandez JM, Martín A, Lopez Berges C, Orfao A, San Miguel JF
    Blood 2007, 110 (7): 2586-92
  • Multiple Myeloma
    García-Sanz R, Mateos MV, San Miguel JF
    Med Clin, 2007, 129 (3):104-15
  • Immunoglobulin gene rearrangements and the patogenesis of multiple myeloma
    Gonzalez D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, Gonzalez M, van Dongen JJ, San Miguel JF, Morgan GJ.
    Blood 2007,119(9): 3112-21
  • Recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
    Bagan J, Bladé J, Cozar JM, Constela M, García-Sanz R, Gomez Veiga F, Lahuerta JJ, Lluch A, Massuti B, Morote J, San Miguel JF, Solsona E.
    Med Oral Patol Cir Bucal 2007, 12 (4): E336-40
  • Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL
    J. Clin Oncol 2007, 25 (25): 3892-901
  • Extended follow –up of a phase 3 trial in relapsed multiple myeloma: final time to event results of the APEX trial
    Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC.
    Blood 2007, 110(10): 3557-3560
  • Use of Bortezomib in the management of chronic graft versus host disease among multiple myeloma patients relapsing after allogeneic transplantation.
    Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernandez E, Etxebarria J, San Miguel JF.
    Haematologica 2007, 92 (9): 1295-6
  • Phase II Pethema trial of alternating Bortezomib and Dexamethasone as induction regimen before autologous stem cell transplantation in younger patients with mulktiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosinol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutierrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J
    J. Clin Oncol 2007, 25 (28): 4452-8
  • In leukapheresis products from non-Hodgkin´s lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression
    Villaron EM, Almeida J, Lopez-Holgado N, Sánchez-Guijo FM, Alberca M, Blanco B, Sánchez-Abarca LI, Lpez O, Pérez-Simón JA, San Miguel JF, Del Cañizo MC.
    Transfus Apher Sci 2007, 37: 145-156
  • Molecular biology of Myeloma
    Gutierrez NC, García-Sanz R, San Miguel JF.
    Clin Transl Oncol 2007, 9(10):618-24
  • Prognostic factors and staging in multiple myeloma
    Fonseca R, San Miguel J.
    Hematol Oncol Clin North Am 2007, 21 (6): 1115-40
  • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynka A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD.
    N Engl J. Med 2007, 357(21): 2123-32
  • Veno-occlusive disease of the liver after high dose cytoreductive therapy with busulfan and melphalna for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ, Spanish Myeloma Group / Pethema
    Biol Blood Marrow Transpl. 2007, 13 (12): 1448-54
  • Should profylactic granulocyte –colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos M.V, García-Sanz R, Colado E, Olazabal J, San-Miguel J.
    Br J Haematol 2007, 140 (3):324-6
  • Bortezomib in multiple myeloma
    Mateos MV, San Miguel JF
    Best Pract Res Clin Haematol , 2007, 20 (4): 701-15
  • Molecular characterization of complete an incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia.
    Martín-Jiménez P, García-Sanz R, González D, Balanzategui A, Pérez JJ, Caballero MD, Sarasquete ME, Galende J, Orfao A, López Berges MC, San Miguel JF, González M.
    Clin Lymphoma Myeloma 2007, 7(9):573-9
AÑO 2008
  • Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clinical Cancer . Francesc Bosch, Ana Ferrer, Neus Villamor, Marcos González, Javier Briones, Eva González-Barca, Eugenia Abella, Santi Gardella, Lourdes Escoda, Elena Pérez-Ceballos, Antoni Asensi, Mª José Sayas, Llorenç Font, Albert Altés, Ana Muntañola, Paola Bertazzoni, María Rozman, Eva Giné, and Emili Montserrat. Research 2008; 14: 155-161.
  • Causes and Prognostic Factors of Remission Induction Failure in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Idarubicin. Javier de la Serna, Pau Montesinos, Edo Vellenga, Chelo Rayón, Ricardo Parody, Angel León, Jordi Esteve, Juan M. Bergua, Gustavo Milone, Guillermo Debén, Concha Rivas, Marcos González, Mar Tormo, Joaquín Díaz-Mediavilla, Jose D. González, Silvia Negri, Elena Amutio, Salut Brunet, Bob Lowenberg, and Miguel A. Sanz. Blood, 2008. 111:3395-402.
  • Association between the proliferative rate of neoplastic B-cells, their
    maturation stage and underlying cytogenetic abnormalities in B-cell chronic
    lymphoproliferative disorders: analysis of a series of 432 patients. Sandra Quijano, Antonio Lopez, Ana Rasillo, Susana Barrena, Maria Luz Sanchez, Juan Flores, Carlos Fernandez, Jose Maria Sayagues, Carlos
    Salvador Osuna, Nuria Fernandez, Marcos Gonzalez, Pilar Giraldo, Manuel Giralt, Maria Carmen Perez, Jose Manuel Martin-Antoran, Oliver Gutierrez, Luis Perdiguer, Joaquin Diaz Mediavilla, Manuel Gonzalez Silva, Agustin Asensio del Rio, Carlos Cervero, Jose Luis Guerra, Rosario Butron, Maria del Carmen Garcia, Julia Almeida, and Alberto Orfao. Blood, 2008, 111: 5130 – 5141.
  • Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
    Hernández-Espinosa D, Miñano A, Martínez C, Ordoñez A, Pérez-Ceballos E, de Arriba F, Mota RA, Ferrer F, González M, Vicente V, Corral J. Lab Invest. 2008; 88:306-17.
  • Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Miguel A. Sanz, Pau Montesinos, Edo Vellenga, Chelo Rayón, Javier de la Serna, Ricardo Parody, Juan M. Bergua, Angel León, Silvia Negri, Marcos González, Concha Rivas,Jordi Esteve, Gustavo Milone, José D. González,Elena Amutio, Salut Brunet,J. García-Laraña, Dolors Colomer, María J. Calasanz, Carmen Chillón, Eva Barragán, Pascual Bolufer, Bob Lowenberg. Blood, 2008; 112:3130-3134.
  • Phase III Randomized Study of Consolidation Therapy with 90Y-Ibritumomab Tiuxetan after First Remission in Advanced Follicular Lymphoma. Franck Morschhauser, John A. Radford, Achiel Van Hoof, Umberto Vitolo, Pierre Soubeyran, Herve Tilly, Peter C. Huijgens, Arne Kolstad, Francesco d’Amore, Marcos Gonzalez Diaz, Mario Petrini, Catherine Sebban, Pier Luigi Zinzani, Marinus H.J. van Oers, Wim van Putten, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Jens Kuhlmann, and Anton Hagenbeek for First-line Indolent Trial (FIT) Investigators. J Clin Oncol, 2008, 26:5156-64
  • Expanded cells in monoclonal TCR +/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens.
    Arancha Rodriguez-Caballero, Andres C Garcia-Montero, Paloma Barcena, Julia Almeida, Francisco Ruiz-Cabello, Maria Dolores Tabernero, Pilar Garrido, Santiago Munoz-Criado, Yorick Sandberg, Anton W Langerak, Marcos Gonzalez, Ana Balanzategui, and Alberto Orfao. Blood 2008; 112:4609-4616.
  • Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martin-Jimenez P, Maria Hernandez J, Rigolin GM, Cuneo A. Br. J. Haematol, 2008; 142:529-37.
  • R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica. 2008,93(12):1829-36.
  • Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain.
    Sancho JM, Morgades M, Alonso N, Deben G, Fernández de Sevilla A, Vázquez L, Nicolás C, García Vela JA, Arranz R, Abella E, Canales MA, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A, Ribera JM; investigators of QUIT Study (PETHEMA, GELTAMO and GOTEL Groups).
    Med Clin (Barc). 2008 ;131(12):441-6.
  • Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol. 2008 ; 26(4):577-84.
  • The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S
    Biol Blood Marrow Transplant. 2008;14(11):1288-97.
  • Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool .J. García-Castro, C. Trigueros, J. Madrenas, JA. Pérez-Simón, R. Rodriguez, P. Menendez. J. Cell. Mol. Med. 2008; 12( 6B): 2552-2565
  • Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease. Díez-Campelo M, Sánchez-Guijo F, Pérez-Simón JA. /Expert Opin Investig Drugs. 2008;17(9):1389-401.
  • Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients.Gonzalez-Porras J, Graciani I, Pérez-Simon JA, Martín-Sanchez JA, Encinas C, Conde MP, Nieto MJ, Corral M. Transfusion. /2008 Jul;48(7):1318-24
  • Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.
    Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero MD. Hematol Oncol. 2008;26(3):171-8.
  • Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N. J Clin Oncol. 2008 ;26(3):455-62
  • High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N; Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. .J Clin Oncol. 2008;26(2):218-24.
  • Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, García-Marco JA, Volin L, Schmitz N, Schwerdtfeger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P. J Clin Oncol. 2008 ;26(31):5094-100
  • Gutiérrez A, Caballero MD, Pérez-Manga G, Rodriguez J. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant. 2008; 42(12):773-81
  • A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N.
    Haematologica. 2008 ;93(3):405-12.
  • BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia.José-Enériz ES, Román-Gómez J, Cordeu L, Ballestar E, Gárate L, Andreu EJ, Isidro I, Guruceaga E, Jiménez-Velasco A, Heiniger A, Torres A, Calasanz MJ, Esteller M, Gutiérrez NC, Rubio A, Pérez-Roger I, Agirre X, Prósper F.
    Br J Haematol. 2008 Aug;142(4):571-82
  • Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response. Olazábal J, García JL, Gutiérrez NC, Sierra M, González M, Hernández JM. Cancer Genet Cytogenet. 2008 Oct 15;186(2):125-6.
  • Detailed Immunophenotyping characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Hernández-Campo P, Almeida J, Jara M, Sanchez ML, Alberca I, Vidriales B, Martínez E, Romero JR, Orfao A. Transfusion, 2008; 48(7):1403-14.
  • New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY).
    Baró C, Salido M, Espinet B, Astier L, Domingo A, Granada I, Millà F, Carrió A, Costa D, Luño E, Hernández JM, Campo E, Florensa L, Ferrer A, Salar A, Bellosillo B, Besses C, Serrano S, Solé F. Leuk Res. 2008; 32: 727-736.
  • Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.Cavazzini F, Hernandez JA, Gozzetti A, Russo Rossi A, De Angeli C, Tiseo R, Bardi A, Tammiso E, Crupi R, Lenoci MP, Forconi F, Lauria F, Marasca R, Maffei R, Torelli G, Gonzalez M, Martin P, Hernandez JM, Rigolin GM, Cuneo A. Br J Haematol. 2008; 142: 529-37.
  • Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F. Haematologica. 2008; 93: 1001-8.
  • An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. Br J Haematol. 2008; 142: 802-7.
  • Emergency surgery of the abdominal aorta in a porcine model: two sequential experiments.
    Lozano FS, Rodríguez JM, García-Criado FJ, Gonzalez-Porras JR, Sanchez-Guijo FM, Sanchez-Conde P, García-Sanchez JE.
    World J Surg. 2008 Apr;32(4):642-7.
  • Surgery of vagal paragangliomas: six patients and review of literature. Lozano FS, Gómez JL, Mondillo MC, González-Porras JR, González-Sarmiento R, Muñoz A. Surg Oncol. 2008;17:281-7.
  • Primary aortoduodenal fistula: new case reports and a review of the literature. Lozano FS, Muñoz-Bellvis L, San Norberto E, Garcia-Plaza A, Gonzalez-Porras JR. J Gastrointest Surg. 2008;12:1561-5.
  • Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
    Sánchez-Guijo FM, López-Jiménez J, González T, Santamaría C, González M, Del Cañizo MC.
    Leuk Res. 2008 Nov 25: 20-22
  • Beclometasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease.
    Díez-Campelo M, Sánchez-Guijo FM, Pérez-Simón JA.
    Expert Opin Investig Drugs 2008 , 17(9):1389-401
  • p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC.
    Br J Haematol. 2008, 141(5):598-606
  • Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
    Martínez-Sánchez P, Montejano L, Sarasquete ME, García-Sanz R, Fernández-Redondo E, Ayala R, Montalbán MA, Martínez R, García Laraña J, Alegre A, Hernández B, Lahuerta JJ, Martínez-López J.
    Br J Haematol. 2008, 142(5):766-74
  • Surgery of vagal paragangliomas: six patients and review of literature.
    Lozano FS, Gómez JL, Mondillo MC, González-Porras JR, González-Sarmiento R, Muñoz A.
    Surg Oncol.2008, 17(4):281-7
  • Tubes for pretransfusion testing should be collected by blood bank staff and hand labelled until the implementation of new technology for improved sample labelling. Results of a prospective study.
    Gonzalez-Porras JR, Graciani IF, Alvarez M, Pinto J, Conde MP, Nieto MJ, Corral M.
    Vox Sang. 2008, 95(1):52-6
  • AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A, Ordóñez A, España F, González-Porras JR, Lecumberri R, Fontcuberta J, Llamas P, Marín F, Estellés A, Alberca I, Vicente V, Corral J.
    Haematologica.2008, 93(5):729-34
  • Primary aortoduodenal fistula: new case reports and a review of the literature.
    Lozano FS, Muñoz-Bellvis L, San Norberto E, Garcia-Plaza A, Gonzalez-Porras JR.
    J Gastrointest Surg. 2008, 12(9):1561-5
  • Emergency surgery of the abdominal aorta in a porcine model: two sequential experiments.
    Lozano FS, Rodríguez JM, García-Criado FJ, Gonzalez-Porras JR, Sanchez-Guijo FM, Sanchez-Conde P, García-Sanchez JE.
    World J Surg. 2008, 32(4):642-7
  • High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
    Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D.
    Cancer. 2008, 113(1):117-25
  • The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ haematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.
    Matarraz S, López A, Barrena S, Fernandez C, Jensen E, Flores J, Bárcena P, Rasillo A, Sayagues JM, Sánchez ML, Hernandez-Campo P, Hernandez Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Orfao A.
    Leukemia. 2008, 22(6):1175-83
  • Argentine Consensus of Congenital Toxoplasmosis
    Durlach R, Kaufer F, Carral L, Freuler C, Ceriotto M, Rodriguez M, Freilij H, Altcheh J, Vazquez L, Corazza R, Dalla Fontana M, Arienti H, Sturba E, Gonzalez Ayala S, Cecchini E, Salomon C, Nadal M, Gutierrez N, Guarnera E.
    Medicina (B Aires). 2008, 68(1):75-87
  • An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
    Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L.
    Vox Sang. 2008, 94(4):315-23
  • Prevention of thalidomide and lenalidomide associated thrombosis in myeloma
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Nievizky R, Waage A, von Lilienfeld-Toal M, Lonial S, morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, Sezer O
    Leukemia 2008, 22: 414-423
  • The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ inmature phenotype.
    Colado E, Alvarez –Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica 2008, 93(1): 57-66
  • Efficacy and safety of Bortezomib in patients with renal impairment: results from the APEX phase 3 study.
    San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben –Yehuda D, Lonial S, Goldsmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC.
    Leukemia 2008, 22: 842- 849
  • Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.
    Martín-Ayuso M, Almedia J, Pérez-Andrés M, Cuello R, Galende J, González-Fraile MI, Martín-Nuñez G, Ortega F, Rodríguez MJ, San-Miguel JF, Orfao A.
    Oncologist 2008, 13(1): 82-92
  • Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the international Myeloma working group
    Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Bladé J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Sonneveld P, Crowley J,
    Blood 2008, 111(8): 4039-47
  • Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
    Rawstrom AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateos G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE, on behalf of the European Myeloma Network.
    Haematologica 2008, 93(3):431-8
  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.
    Haematologica. 2008, 93(4):560-5
  • The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P, Ocio EM, Garayoa M, Montero JC, Hoffmann F, García-Echevarria C, Zimmermann J, Pandiella A, San Miguel JF.
    Br J Haematol 2008, 141 (4): 470-82
  • Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
    Armellini A, Sarasquete ME, García Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfao A, Gutierrez NC, González M, San Miguel JF.
    Br. J. Haematol. 2008, 141(2):212-5
  • The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease.
    Alcoceba M, Marín L, Balanzategui A, Sarasquete ME, Martín-Jiménez P, Chillón MC, Corral R, Pérez-Persona E, Fernández –Calvo FJ, Hernández JM, Bladé J, Lahuerta JJ, González M, San Miguel JF, García-Sanz R.
    Tissue Antigens 2008, 71(6): 548-51
  • Individualizing treatment of patients with myeloma in the era of novel agents
    San Miguel J, Harousseau JL, Joshua D, Anderson KC
    J. Clin. Oncolo. 2008, 26(16):2761-6, 2008
  • Expression of c-kit isoforms in multiple myeloma: differences in signalling and drug sensitivity.
    Montero JC, López-Pérez R, San-Miguel JF, Pandiella A.
    Haematologíca 2008, 93(6):851-9
  • Prognostic value of Immunophenotyping Multiple Myeloma: a study by the GEM and the and the Pethema cooperative study groups on Patients Uniformly treated with high dose therapy
    Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Díaz –Mediavbilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF.
    J Clin Oncol 2008, 26(16): 2737-44
  • Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification.
    Carrancio S, López-Holgado N, Sánchez-Guijo FM, Villarón E, Barbado V, Tabera S, Diez-Campelo M, Blanco J, San Miguel JF, Del Cañizo MC.
    Exp Hematol 2008, 36(8): 1014-1021
  • Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators.
    Cancer , 2008: 112(7):1529-37
  • Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF; Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant 2008, 14(6):664-71
  • Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
    Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC.
    Cancer Res. 2008, 68(13):5216-25
  • Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphims of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphisms analysis.
    Sarasquete ME, García-Sanz R, Marin L , Alcoceba M, Chillón MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, Gonzalez M, San Miguel JF.
    Blood 2008, 112(7): 2709-2712
  • A prospective pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioningallogeneic transplantation in newly diagnosed multiple myeloma.
    Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, hernandez B, García-Frade J, Carrera D, Leon A, Hernandez M, Fernandez Abellan P, Bergua JM, San-Miguel J, Blade J.
    Blood 112(9):3591-3, 2008
  • The effect of mesenchymal stem cells on the viability, proliferation and differentation of B-lymphocytes.
    Tabera S, Perez-Simón JA, Diez-Campelo M, Sánchez-Abarca LI, López A, Benito A, Ocio E, Sanchez-Guijo FM, Cañizo C, San-Miguel JF.
    Haematologica, 2008, 93(9):1301-9
  • Clinical impact of human Jurkat T-cell-line–derived antithumocyte globulin in multiple myeloma patinets undergoing allogeneic stem cell transplantation. Ayuk F, Pérez-Simón JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N. Haematologica,2008, 93(9):1343-50
  • Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous ítem cell transplantation.
    Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, G Gutierrez NC, Garcia de Coca A, de las Heras N, Mateos MV, Lopez-Berges MC, García-Boyero R, Galende J, Hernandez J, Palomera L, Carrera D, Martinez R, de la Rubia J, Martin A, Blade J, Lahuerta JJ, Orfao A, San Miguel JF Blood 2008, 112 (10): 4017-23
  • Characterization of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
    Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL
    Br J. Haematol 2008, 143 (2): 222-9
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    San Miguel JF, Schlag R, Khuageva NK,Dimopoulos MA, Sphilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL; Liu K, Cakana A, van de Velde H, Richardson PG; Vista trial investigators.
    N Engl J. Med 2008, 359 (9):906-17
  • Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
    Perez-Simón JA, Encinas C, Silva F, Arcos MJ, Diez-campelo M, Sánchez-Guijo FM, Colado E, Martín J, Vázquez L, del Cañizo C, Caballero D, San Miguel J.
    Biol Blood Marrow Transplant, 2008, 14(10):1163-71
  • The relevante of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leucemia.
    Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, González M.
    Haematologica 2008, 93(12): 1797-805
  • Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting.
    Alcoceba M, Balanzategui A, Díez-Campelo M, Martín-Jimenez P, Sarasquete ME, Chillón MC, Santamaría C, Pérez-Simón JA, Marín L, Caballero MD, San Miguel JF, García-Sanz R, González M.
    Transplantation 2008, 86(7): 983-90
  • Bortezomib is associated with better health related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
    Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC.
    Br. J. Haematol 2008, 143 (4): 511-9
  • Influence of Pre-and Post Transpalntation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF
    J. Clin Oncol 2008, 26(35): 5775-82
  • Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ, for the Doxil-Mmy-3001 Study investigators
    Clin Lymphoma Myeloma 2008, 8 (6): 352-355
  • Recent phase III trials in the Frontline treatment of multiple myeloma: evaluating their impact on community practice.
    J. San-Miguel, T. Facon, M. Cavo
    Clinical Advances in Hematology & Oncology, 2008, vol. 6 (4), suppl. 10: 1-10
  • New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
    Ocio EM, Mateos MV, Maiso P, Pandiella A, San Miguel JF.
    Lancet Oncol.2008, 9 (12): 1157-65
AÑO 2009
  • Increased frequency (12%) of circulating chronic lymphocytic leukemia-like
    B-cell clones in healthy subjects using a highly sensitive multicolor flow
    cytometry approach Wendy G. Nieto, Julia Almeida, Alfonso Romero, Cristina Teodosio, Antonio Lopez, Ana F. Henriques, Maria Luz Sanchez, Maria Jara-Acevedo, Ana Rasillo, Marcos Gonzalez, Paulino Fernandez-Navarro, Tomas Vega, Alberto Orfao, and the Primary Health Care Group of Salamanca for the Study of MBL. Blood 2009; 114: 33-37.
  • Molecular and Epidemiological findings of childhood acute leukemia in Costa Rica . Santamaría C, Vargas M, Venegas P,, Calvo M, Obando C, Valverde B, Cartín W, Carrillo JM , Jimenez R, González M. J. Pediatr Hematol Oncol. 2009; 31:131-135.
  • Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline chemotherapy: characteristics, outcome and prognostic factors Pau Montesinos, Juan M. Bergua, Edo Vellenga, Chelo Rayón, Ricardo Parody, Javier de la Serna, Angel León, Jordi Esteve, Gustavo Milone, Guillermo Debén, Concha Rivas, Marcos González, Mar Tormo, Joaquín Díaz-Mediavilla, Jose D. González, Silvia Negri, Elena Amutio, Salut Brunet, Bob Lowenberg, and Miguel A. Sanz.. Blood, 2009; 113:775-783.
  • Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion.
    Rosa Pérez-Grande, Nieves Gutiérrez-Zufiaurre, Santiago Muñoz-Criado, Ana M. Blázquez de Castro, Lourdes Vázquez López, Francisco González San Martín, Jose Angel García Rodríguez, Juan Luis Muñoz Bellido
    Diagn Microbiol Infect Dis. 2009 May;64(1):80-2.
  • Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N; Lymphoma Working Party of the EBMT. Haematologica. 2009;94(2):230-8
  • Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.Ann Hematol. 2009 Aug 19.
  • Sáez AI, García-Cosío M, Sáez AJ, Hernández JM, Sánchez-Verde L, Álvarez D, de la Cueva P, Arranz R, Conde E, Grande C, Rodríguez J, Caballero D, Piris MA. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for DLBCL patients. Leuk Lymphoma 2009; 50: 571-81.
  • Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. (European Group for Blood and Marrow Transplantation). Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascon J, Fauser AA, Michallet M, López-Corral L, Neuburger S, Tridello G, Einsele H. “Clin Infect Dis. 2009 Jul 15;49(2): 233-40.
  • Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy.
    Pérez-Ilzarbe M, Díez-Campelo M, Aranda P, Tabera S, Lopez T, del Cañizo C, Merino J, Moreno C, Andreu EJ, Prósper F, Pérez-Simón JA.
    Transfusion. 2009, 49 (9 ):1901-10
  • Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
    Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular).
    Biol Blood Marrow Transplant. 2009 May;15(5):639-42.
  • Multiparametric comparison of mesenchymal stromal cells obtained from trabecular bone by using a novel isolation method with those obtained by iliac crest aspiration from the same subjects.
    Sanchez-Guijo FM, Blanco JF, Cruz G, Muntion S, Gomez M, Carrancio S, Lopez-Villar O, Barbado MV, Sanchez-Abarca LI, Blanco B, Briñon JG, del Cañizo MC.
    Cell Tissue Res. 2009 Jun;336(3):501-7.
  • Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
    Sanchez-Guijo FM, Lopez-Jimenez J, Gonzalez T, Santamaría C, González M, Del Cañizo MC.
    Leuk Res. 2009 Jun; 33(6):e20-2.
  • Functional analysis of killer Ig-like receptor-expressing cytomegalovirus-specific CD8+ T cells.
    van der Veken LT, Campelo MD, van der Hoorn MA, Hagedoorn RS, van Egmond HM, van Bergen J, Willemze R, Falkenburg JH, Heemskerk MH
    .J Immunol. 2009 Jan 1;182(1):92-101.
  • Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study.
    Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascon J, Fauser AA, Michallet M, López-Corral L, Neuburger S, Tridello G, Einsele H. “ (European Group for Blood and Marrow Transplantation).
    Clin Infect Dis. 2009 Jul 15;49(2): 233-40.
  • Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.
    J Clin Oncol. 2009 Sep 20;27(27):4578-84.
  • A randomized phase 3 study of tipifarnib compared to best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older.
    Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ
    Blood. 2009 Aug 6;114(6):1166-73.
  • Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.
    Ribera JM, Oriol A, González M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, Martín-Reina V, Sarrá J, Parody R, Pérez de Oteyza J, Bureo E, Bernal MT; on behalf of the Programa Español de Tratamiento en Hematología (PETHEMA) and Grupo Español de Trasplante Hemopoyético (GETH) Groups.
    Haematologica. 2009 Oct 1:87-95.
  • Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.
    Menendez P, Catalina P, Rodríguez R, Melen GJ, Bueno C, Arriero M, García-Sánchez F, Lassaletta A, García-Sanz R, García-Castro J.
    J Exp Med. 2009 Dec 21;206(13):3131-41.
  • Primary Cutaneous Localized Amyloid Elastosis.
    Santos-Briz A, Cañueto J, Antúnez P, Bravo J, García-Sanz R, de Unamuno P.
    Am J Dermatopathol. 2009 Oct 30.: 86-90
  • Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP.
    J Clin Oncol. 2009 Jan 1;27(1):120-6.
  • International prognostic scoring system for Waldenstrom macroglobulinemia.
    Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. Blood. 2009 Apr 30;113(18):4163-70.
  • Femoral vein injury and transposition techniques: a new approach to venous reconstruction in the setting of trauma.
    Lozano FS, Estevan MC, Gónzalez-Porras JR.
    J Trauma. 2009 Oct;67(4):E118-20.
  • An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty.
    Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M.
    Transfus Med. 2009 Feb;19(1):35-42.
  • Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment.
    Alvarez-Larrán A, del Río-Garma J, Pujol M, de la Rubia J, Hernández-Jodra M, Borrell M, González-Porras JR, García-Gala JM, Viejo A, Enríquez L, Arbona C, García-Erce JA, Noblejas AG, Pereira A.
    Ann Hematol. 2009 Oct;88(10):973-8.
  • Surgery of vagal paragangliomas: six patients and review of literature.
    Lozano FS, Gómez JL, Mondillo MC, González-Porras JR, González-Sarmiento R, Muñoz A.
    Surg Oncol. 2008 Dec;17(4):281-7.
  • Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura.
    Julia A, Kovaleva L, Loria S, Alberca I, Hernandez F, Sandoval V, Sierra J, Vidaller A, Ayguasanosa J, Carretero M.
    Transfus Med. 2009 Oct;19(5):260-8.
  • International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
    Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H.
    Leukemia. 2009 Dec;23(12):2210-21.
  • Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
    Robledo C, García JL, Caballero D, Conde E, Arranz R, Flores T, Grande C, Rodríguez J, García E, Sáez AI, González M, Gutiérrez NC, Piris MA, Hernández JM; Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group (GEL-TAMO).
    Cancer. 2009 Aug 15;115(16):3728-37.
  • Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA.
    Haematologica. 2009 Nov 10. [Epub ahead of print]
  • Array CGH identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
    Robledo C, Garcia JL, Caballero D, Conde E, Flores T, Rodríguez J, Arranz R, García E, Sáez AI, Grande C, González M, Gutiérrez NC, Piris MA, Hernández JM. Cancer 2009; 115: 3728-37237.
  • Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for DLBCL patients.
    Sáez AI, García-Cosío M, Sáez AJ, Hernández JM, Sánchez-Verde L, Álvarez D, de la Cueva P, Arranz R, Conde E, Grande C, Rodríguez J, Caballero D, Piris MA.
    Leuk Lymphoma 2009; 50: 571-81.
  • Microarray classification of myelodysplastic syndrome (MDS) identifies subgroups with distinct clinical outcomes and identifies patients with high risk of AML transformation.
    Mills KI, Kohlmann A, Williams M, Wieczorek L, Liu WM, Li R, Wen W, Bowen DT, Loeffler H, Hernandez JM, Hofmann WK, Haferlach T.
    Blood 2009; 114: 1063-72.
  • GeneCBR: a translational tool for multiple-microarray analysis and integrative information retrieval for aiding diagnosis in cancer research.
    Glez-Peña D, Díaz F, Hernández JM, Corchado JM, Fdez-Riverola F. BMC Bioinformatics. 2009; 10: 187.
  • Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion. 2009 Aug 28.(ahead of print)
  • Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
    Pettengell R, Aapro M, Brusamolino E, Caballero D, Coiffier B, Pfreundschuh M, Trneny M, Walewski J.
    Clin Drug Investig. 2009;29(8):491-513.
  • R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.
    Martín A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea.
    Haematologica. 2009 May; 94 (5): 744.
  • Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.
    Gallardo D, de la Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A, Vallejo C, Martín C, Caballero D, Brunet S, Serrano D, Solano C, Ribera JM, de la Rubia J, Carreras E.
    Haematologica. 2009 Sep; 94(9):1282-8.
  • Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation.
    Santos-Briz A, Romo A, Antúnez P, Román C, Alcoceba M, Garcia JL, Vazquez L, González M, Unamuno P.
    Clin Exp Dermatol. 2009 Oct 10.
  • Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J, Montesinos P, Martino R, Jarque I, Rovira M, Vázquez L, López J, Batlle M, de la Cámara R, Juliá A, Lahuerta JJ, Debén G, Díaz J, García R, Sanz MA.
    Biol Blood Marrow Transplant. 2009 Apr;15(4):512-6
  • Solubre and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease
    Pérez-Andrés M, Almeida J, Martín Ayuso M, De las Heras N, Moro MJ, Martín –Nuñez G, Galende J, Cuello R, Abuín I, Moreno I, Dominguez M, Hernández J, Mateos G, San Miguel JF, Orfao A.
    Int J. Cancer 2009, 124 (2):367-375
  • Zalysis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double strand breaks.
    Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San Miguel JF, Pandiella A.
    Blood 2009, 113(16): 3781-91
  • Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response
    Fermín M. Sánchez –Guijo, Jesús M. Henandez, Eva Lumbreras, Patricia Morais, Carlos Santamaría, Juan-Luis García, Norma C. Gutierrez, Jesús F. San Miguel, María Consuelo del Cañizo.
    Leukemia Research 2009, 33:170-173
  • Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Diez-Campelo M, Pérez-Simón JA, Pérez J, Alcoceba M, Richtmon J, Vidriales B, San Miguel J.
    Am J. Hematol. 2009, 84 (3): 149-52
  • The research mission in myeloma
    Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC.
    Leukemia 2009, 23 (2): 422-3
  • International Myeloma Working group guidelines for serum–free light chain analysis in multiple myeloma and related disorders.
    Dispenzieri A, kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseay JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG. International Myeloma Working group.
    Leukemia, 2009, 23 (2): 215- 24
  • Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome.
    Lopez-Villar O, García JL, Sánchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez Simón JA, Hernández-Rivas JM, San-Miguel J, Del Cañizo MC.
    Leukemia 2009, 23(4):664-72
  • Reversibility of syntomatic peripheral neuropathy with bortezomib in the phase II APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson P, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh J, Boral A, Esseltine D, Wen P, Amato A, Anderson K, San Miguel J.
    Br J. Haematol 2009, 144 (6):895-903,
  • Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P
    Blood rev. 2009, 23(2):87-93
  • A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
    Hernández JA, Rodriguez AE, González M, Benito R, Fontanillo C, Sandoval V, Romero M, Martín-Núñez G, de Coca AG, Fisac R, Galende J, Recico I, Ortuño F, García JL, de las Rivas J, Gutierrez NC, San Miguel JF, Hernández JM.
    Haematologica 2009, 94(3):364-71
  • Lenalidomide in combination with dexamethaosne at first relapse in combination with its use as later salvage therapy in relapsed or refractory multiple myeloma.
    Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA.
    Eur. J. Haematol 2009, 82(6): 426-32
  • Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with dose from normal donors.
    Garayoa M, García JL, Santamaría C, García-Gómez A, Blanco JF, Pandiella A, Hernández JM, Sánchez-Guijo FM, Del Cañizo MC, Gutierrez NC, San Miguel JF.
    Leukemia 2009 23 (8): 1515-27
  • Frontline treatment in elderly patients with multiple myeloma
    Facon T, San Miguel J, Mateos MV, Hulin C.
    Semen Hematol 2009, 46(2): 133-42
  • Molecular stratification model for prognosis in cytogenetically normal acute myeloid leucemia.
    Santamaria CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández –Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San-Miguel JF, González M.
    Blood 2009, 114 (1): 148-52
  • Bisphosphonate-related osteonecrosis:genetic and acquired risk factors.
    Sarasquete M, González M, San Miguel J, García-Sanz R.
    Oral Dis 2009, 15 (6): 382-7
  • High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
    Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán, Rodriguez JN, Fernández- Abellán P, Bárez A, Peñarrubia MJ, Vidriales MB, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, González M.
    Leuk Res.2009, 33(12): 1706-9
  • The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
    Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P.
    Ann Oncol 2009, 20 (8): 1303-17
  • Treatment with Bortezomib of human CD4+T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
    Blanco B, Pérez–Simón JA, Sánchez–Abarca LI, Caballero-Velazquez T, Gutierrez-Cossio S, Hernández-Campo P, Diez –Campelo M, Herrero-Sánchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, del Cañizo C, San Miguel JF.
    Haematologica 2009, 94 (7):975-83
  • International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Besinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Bladé J, Lonial S, Dimopoulos MA. Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardosn PG, Niesvizky R, Rakjkumar SV, Durie BG.
    Leukemia 2009, 23(10): 1904-12
  • Mobilization in myeloma revisited: IMWG consensus perspective on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens.
    Kumar S, Giralt s, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Hajek R, Bergsagel L, Bladé J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV
    Blood 2009, 114 (9):1729-35
  • Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.
    Pérez-Simón JA, Tabera S, Sarasquete ME, Diez-Campelo M, Canchado J, Sánchez-Abarca LI, Blanco B, Alberca I, Herrero-Sánchez C, Cañizo C, San Miguel JF. Cytotherapy 2009, 26: 1-8
  • International myeloma Working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    A. Dispenzieri, R. Kyle, G. Marlini, J San Miguel, H. Ludwig, R. Hajek , A. Palumbo, S. Jagannath, J. Bladé, S. Lonial, M. Dimopoulos, R. Comenzo, H. Einsele, B. Barlogie, K. Anderson, M. Gertz, JL Harousseau, M. Attal, P. Tosi, P Sonneveld, M. Boccadoro, G. Morgan, P. Richardson, O. Sezer, MV Mateos, M. Cavo, D. Joshua, I Turesson, W. Chen, K. Shimizu, R. Powles, SV Rajkumar and BGM Durie on behalf of the International Myeloma Working Group.
    Leukemia 2009, 23: 215-224
  • International myeloma working group (IMWG) consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma
    Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG.
    Leukemia 2009, 23 (9): 1545-56
  • International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
    Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG.
    Leukemia 2009, 23(10):1716-30
  • Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.Villanueva FN, Pérez-Simón JA, Silva FF, Caballero-Velázquez TT, Sánchez-Guijo FF, Cañizo CC, Vázquez LL, Caballero DD, San Miguel JF.Biol Blood Marrow Transplant. 2009, 15(10):1331-6
    .- The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.Paiva B, Vidriales MB, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, de Las Heras N, Mateos MV, Lopez-Berges MC, Garcia-Boyero R, Galende J, Hernandez J, Palomera L, Carrera D, Martinez R, de la Rubia J, Martin A, Gonzalez Y, Blade J, Lahuerta JJ, Orfao A, San Miguel JF.Blood. 2009, 114 (20):4369-72
  • Relapse/Refractory myeloma patient:potential treatment guidelines. San Miguel JF J. Clin Oncol. 2009, 27 (34): 5676-7
  • The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.Maiso P, Colado E, Ocio EM, Garayoa M, Martin J, Atadja P, Pandiella A, San Miguel JF. Leukemia 2009, 23 (12): 2265-74
  • Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marroww plasma cells.Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de las Heras N, de Coca AG, Hernández JM, Galende J, Martín Nuñez G, Bárez A, Alonso JM, Martín A, López-Berges C, Orfao A, San-Miguel JF, Vidriales MB. Br. J. Haematol. 2009 (ahead of print)
  • VMP (Bortezomib, Melphalan and Prednisone) is active and well tolerated in Newly diagnosed patients with multiple myeloma with , moderately impaired renal function and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpliberg O, Kastritis E, Kropff M, Petrucci MY, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel J.J. Clin Oncol. 2009 27 (36): 6086-93
  • How I treat multiple myeloma in younger patients. Stewart AK, Richardson PG, San-Miguel JF. Blood 2009, 114 (27): 5436- 43
  • Guidelines for the use of bisphosphonates in multiple myeloma: recommendations of the expert committee of the Spanuish myeloma group from the PETHEMA group.García-Sanz R, Alegre A, Capote FJ, Hernández JM, Rosiñol L, Rubia JD, Sureda A, Arriba FD, Bargay J, Diaz-Mediavilla J, García-Larña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel J, Bladé J.Med Clin 2009 ( ahead of print)
  • Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.Perez-Simón JA, Tabera S, Sarasquete ME, Díez-campelo M, Canchado J, Sánchez-Abarca LI, Blanco B, Alberca I, Herrero-Sánchez C, Cañizo C, San Miguel J.F. Cytotherapy 2009, 11(6): 698-705
  • Multiparameter flow cytormetry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.Paiva B, Vidriales MB, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM cooperative study group; PETHEMA cooperative study group.Haematologíca 2009, 94 (11):1599-602
  • Immunomodulatory effect of 5-azacytidine (5-azaC) : potential role in the transplantation setting.Sanchez-Abarca L, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, García JL, Carrancio S, Hernández-Campo P, González HJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF, Pérez-Simón JA.Blood 2009, 115 ( 81): 107-21
  • The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant hodgkin´s lymphoma. García-Sanz R, González –López TJ, Vázquez L, Hermida G, Graciani IF, San Miguel J.Eur J. Haematol 2009 (ahead of print)
  • Prospective comparative analysis of the angigenic capacity of manaocytes and CD133+ cells in a murine model of hind limb ischemia.López-Holgado N, Alberca M, Sánchez-Guijo FM, Villarón EM, Rivas JV, López-Novoa JM, Briñón JG, Arévalo MA, Oterino E, Santamaría C, San Miguel JF, del Cañizo MC.Cytotherapy 2009, 11(8):1041-51
  • BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizan JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San-Miguel J, González M.Ann Hematol. 2009 . 2010, 89:453-458. ( Ahead of print).
  • In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San Miguel JF. Haematologica 2009 (Ahead of print)
  • P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.Lopez Anglada L, Gutierrez NC, García JL, Mateos MV, Flores T, San Miguel JF. Eur J. Haematol. 2009 (ahead of print)
  • How to treat a newly diagnosed young patient with multiple myeloma. San-Miguel JF, Mateos MV. Hematology Am. Soc Hematol Educ Program , 2009, 555-65
  • Risk stratification in the era of novel therapies. San-Miguel J, Mateos MV, Gutierrez NC. Cancer J. , 2009, 15 (6): 457-64
  • Both CD 133+ cells and monocyte provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endotelial cells.
    Sanchez-Guijo FM, Oterino E, Barbado MV, Carrancio S, Lopez-Holgado N, Muntion S, Hernandez-Campo P, Sanchez-Abarca LI, Perez-Simón JA, San Miguel JF, Briñon JC, Cañizo NC. Cell Transplant 2009 ( ahead of print)
AÑO 2010
  • Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de las Heras N, de Coca AG, Hernández JM, Galende J, Martín Núñez G, Bárez A, Alonso JM, Martín A, López-Berges C, Orfao A, San-Miguel JF, Vidriales MB.
    Br. J. Haematol. 148 (1):110-4, 2010
  • Immunomodulatory effect of 5-azacytidine (5-azaC) : potential role in the transplantation setting.
    Sánchez-Abarca L, Gutierrez-Cosio S, Santamaría C, Caballero-Velázquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González HJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF, Pérez-Simón JA.
    Blood 115 (1): 107-21, 2010
  • The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant hodgkin´s lymphoma.
    García-Sanz R, González –López TJ, Vázquez L, Hermida G, Graciani IF, San Miguel J.
    Eur J. Haematol 84(3):266-70, 2010
  • BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
    Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizan JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San-Miguel J, González M.
    Ann Hematol. 89(5):453-8, 2010
  • In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San Miguel JF.
    Haematologica 95(5):794-803, 2010
  • P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
    López Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF.
    Eur J. Haematol. 84: 359- 361, 2010
  • Guidelines for the use of bisphosphonates in multiple myeloma: recommendations of the expert committee of the Spanuish myeloma group from the PETHEMA group.
    García-Sanz R, Alegre A, Capote FJ, Hernández JM, Rosiñol L, Rubia JD, Sureda A, Arriba FD, Bargay J, Diaz-Mediavilla J, García-Larña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel J, Bladé J.
    Med Clin 134 (6): 268-278, 2010
  • Both CD 133+ cells and monocyte provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endotelial cells.
    Sanchez-Guijo FM, Oterino E, Barbado MV, Carrancio S, Lopez-Holgado N, Muntion S, Hernandez-Campo P, Sanchez-Abarca LI, Perez-Simón JA, San Miguel JF, Briñon JC, Cañizo NC
    Cell Transplant 19:103-112, 2010
  • Deregulation of microRNA expresion in the different genetic subtypes of multiple myeloma and correlation with gene expresion profiling.
    Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, de la Rivas J, Ticona FV, Fermiñan E, Martín-Jiménez P, Chillón C, Risueño A, Hernández JM, García Sanz R, González M, San Miguel JF
    Leukemia 24(3):629-37, 2010
  • The role of immature platelet fraction in acute coronary syndrome.
    González-Porras JR, Martín-Herrero F, González-López TJ, Olazábal J, Diez-Campelo M, Pabon P, Alberca I, San Miguel JF
    Thromb Haemost. 103 (1): 247-9, 2010
  • Current multiple myeloma treatment strategies with novel agents: a European perspective.
    Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S.
    Oncologist 15(1):247-9, 2010
  • Long FLT3 internal tandem duplications and reduced PML-RAR Ralpha expression at diagnosis characterize a high risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, María Eugenia S, Alcoceba M, Marín L, Caballero MD, Vidriales B, Ramos F, Bernal T, Díaz Mediavilla J, de Coca AG, Peñarrubia MJ. Queizán JA, Giraldo P, San Miguel JF, González M.
    Haematologica 95(5): 745-51, 2010.
  • The DAC system and associations with multiple myeloma
    Ocio EM, San Miguel JF.
    Invest New Drugs 28(1:S28-35), 2010
  • Liver function test and absolute lymphocyte count at day +100 are predictive factors for extensive and sever chronic graft versus host disease after allogenic peripheral blood stem cell transplant.
    Silva F, Pérez-Simón JA, Caballero Velázquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gómez F, Vázquez L, Del Cañizo C, Caballero D, San Miguel J.
    Am J Hematol. 85(4):290-3, 2010
  • Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma updated follow-up and impact of subsequent therapy in the phase III VISTA trial
    Mateo MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilbereg O, Kropff M,Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel J.
    J. Clin Oncol 28(13):2259-66, 2010
  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asyntomatic) multiple myeloma: IMW consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA, Durie BG, Rajkumar SV, Landgren O, Bladé J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumgo A, Richardson PG, Barlogie B, Vescio R, Turesson I, Westin J, Boccadoro M.
    Leukemia 24(6):1121-7, 2010
  • The newly diagnosed myeloma patient. Therapeutic approaches.
    Jesús San-Miguel
    European Oncology , 6(1): 81- 84), 2010.
  • Monoclonal gammopathy of undetermined significance: a consensus statement.
    Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA.
    Br J Haematol. 150(1):28-38, 2010
  • Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
    Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J.
    Clin Cancer Res. ;16(12):3260-9, 2010
  • Value of serum free light chains assay in plasma cell disorders.
    López-Corral L, García-Sanz R, San-Miguel JF
    Med Cli . 135 (8):368-74, 2010
  • Isolation and characterization of mesenchymal stromal cells from human degenerated nucleous pulposus: comparison with Bone marrow mesenchymal stromal cells from the same subjects.
    Blanco JF, Graciani IF, Sánchez-Guijo FM, Muntión S, Hernández-Campo P, Santamaría C, Carrancio S, Barbado MV, Cruz G, Gutiérrez-Cosío S, Herrero C, San Miguel JF, Briñón JG, Del Cañizo MC.
    Spine (Phila Pa 1976). 35(26):2259-65, 2010
  • Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF.
    Blood 116:3743-3750, 2010
  • Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
    Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, De La Rubia J, Rosinol L, Sureda A, Garcia-Larana J, Diaz-Mediavilla J, Hernandez-Garcia MT, Carrera D, Besalduch J, de Arriba F, Oriol A, Escoda L, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF.
    Haematologica. 95(11): 1913-1920, 2010
  • CD117 Expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopietic compartmen and favourable disease features.
    Achmidt-Hieber M, Pérez-Andrés M, Paiva B, Flores J, Gutiérrez N, Vidriales MB, Matarraz S, San Miguel J, Orfao A.
    Haematologica 2010
  • Risk-adapted treatment of acute promyelocytic leukemia based on all trans retinoic acid and anthracycline with addition of cytarabine in consiolidation therapy for high –risk patients: further improvements in treatment outcome.
    Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa Em, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups.
    Blood , 115(25): 5137-46, 2010
  • International Myeloma Working group consensus statement regarding the current status of allogeneic stem cell transplantation for Multiple myeloma
    Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W; International Myeloma Working Group.
    J Clin Oncol. 28(29):4521-30, 2010
  • Treatment of relapsed and refractory multiple myeloma in the era of novel agents.van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.
    Cancer Treat Rev. 2010 Sep 20.
  • Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study.
    Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF.
    Eur J Haematol. 86: 23-31, 2010
  • Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group.
    Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie BG, San Miguel J.
    J Clin Oncol. 28(33):4976-84, 2010
  • Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P.
    Lancet Oncol.;11(11):1086-95, 2010
  • Emerging Therapies for the Treatment of Relapsed or Refractory Multiple Myeloma.
    Dimopoulos MA, San-Miguel JF, Anderson KC.
    Eur J Haematol. 86: 1-15, 2010
  • Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide . Introduction and overview
    San-Miguel J.F
    Blood Rev. 24 Suppl 1: S1-3, 2010
  • Concluding remarks and future directions.
    San Miguel JF
    Blood Rev. 24 Suppl 1: S33-4, 2010
  • Up-regulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in syntomatic myeloma patients.
    Sarasquete ME, Gutiérrez NC, Misiewicz-Krzeminska I, Paiva B, Chillón MC, Alcoceba M, García-Sanz,R, Hernández-Rivas JM, González M, San Miguel JF.
    Haematologica 2010 Dec 15 (Ahead of print)
  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, San Miguel JF.
    Lancet Oncol. 2010 Oct;11(10):934-41.
  • Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, San Miguel JF, Orfao A.
    Cytometry B Clin Cytom. 2010 Jul;78(4):239-52. Review.
  • Survival and years of life lost in different age cohorts of patients with multiple myeloma.
    Ludwig Heinz, Bolejack Vanessa, Crowley John, Blade Joan, San Miguel Jesús, Kyle Robert, Rajkumar Vincent, Shimizu Kazuyuki, Turesson Ingemar, Westin Jan, Sonneveld Pieter, Cavo Michele, Boccadoro Marioo, Palumbo Antonio, Tosi Patrizia, Harousseau Jean-Luc, Attal Michel, Barlogie Bart, Stewart A Keith, Durie Brian
    Journal of Clinical Oncology 28(9):1599-1605, 2010
  • Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.
    Ribera JM, Oriol A, González M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, Martín-Reina V, Sarrá J, Parody R, de Oteyza JP, Bureo E, Bernal MT; Programa Español de Tratamiento en Hematología; Grupo Español de Trasplante Hemopoyético Groups.
    Haematologica. 2010 Jan;95(1):87-95
  • Cytogenetic risk stratification in chronic myelomonocytic leukemia.
    Such E, Cervera J, Costa D, Sole' F, Vallespí T, Luno E, Collado R, Calasanz MJ, Hernandez-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, Del Canizo C, Gomez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF.
    Haematologica. 2010 Nov 25. [Epub ahead of print]
  • Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol. 2010 Feb;89(2):147-54. Epub 2009 Aug 19.
  • Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs.
    González-López TJ, Sánchez-Guijo FM, Ortín A, Crusoe E, Cordoba I, Corral M, Vázquez L, Caballero MD.
    Bone Marrow Transplant. 2010 Oct 18. [Epub ahead of print] No abstract available.
  • Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant.
    López-Anglada L, Vázquez L, Pérez-Simón JA, Dávila I, Santos-Briz A, García L, Caballero D.
    Bone Marrow Transplant. 2011 Jan 10. [Epub ahead of print]
  • Helicobacter pylori Infection and Graft-versus-Host Disease.
    Velasco Guardado A, López-Corral L, Pérez-Simón JA, Caballero-Velázquez T, Flores Corral T, Caballero Barrigón D, Rodríguez Pérez A.
    Biol Blood Marrow Transplant. 2010 Nov 18. [Epub ahead of print]
  • European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
    Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A.
    Leuk Lymphoma. 2010 Nov;51(11):2006-11. Epub 2010 Aug 31
  • Limbus damage in ocular graft-versus-host disease.
    Pérez RL, Pérez-Simón JA, Caballero-Velázquez T, Flores T, Carrancio S, Herrero C, Blanco B, Gutierrez-Cosio S, Cañete-Campos C, González FC, Hernández-Galilea E, Sánchez-Abarca I.
    Biol Blood Marrow Transplant. 2010 Aug 25. [Epub ahead of print]
  • p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation.
    Sardina JL, López-Ruano G, Sánchez-Abarca LI, Pérez-Simón JA, Gaztelumendi A, Trigueros C, Llanillo M, Sánchez-Yagüe J, Hernández-Hernández A.
    Cell Death Differ. 2010 Dec;17(12):1842-54. Epub 2010 Jun 4.
  • Immunomodulatory effect of mesenchymal stem cells.
    Herrero C, Pérez-Simón JA.
    Braz J Med Biol Res. 2010 May; 43(5):425-30. Epub 2010 Apr 23. Review.
  • Monoclonal free light chains can be found in heavy chain diseases.
    López-Anglada L, Puig N, Díez-Campelo M, Alonso-Ralero L, Barrena S, Aparicio MA, Gutiérrez NC, García-Sanz R.
    Ann Clin Biochem. 2010 Nov;47(Pt 6):570-2. Epub 2010 Oct 7.
  • Novel treatment regimens for Waldenström's macroglobulinemia.
    García-Sanz R, Ocio EM.
    Expert Rev Hematol. 2010 Jun;3(3):339-50.
  • A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.
    Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group.
    Blood. 2010 Aug 26;116(8):e12-7.
  • Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
    Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Leal da Costa F, Garcia Sanz R, Schey S, Facon T, Morgan G, Moreau P.
    Ann Hematol. 2010 Aug;89(8):803-11.
  • Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.
    Sayagués JM, Fontanillo C, Abad Mdel M, González-González M, Sarasquete ME, Chillon Mdel C, Garcia E, Bengoechea O, Fonseca E, Gonzalez-Diaz M, De las Rivas J, Muñoz-Bellvis L, Orfao A.
    PLoS One. 2010 Oct 29;5(10):e13752.
  • Open and endovascular treatment for pseudoaneurysms of the superior mesenteric artery.
    Díaz E, Lozano FS, González S, Alcázar JA, Torres JA, Gónzalez-Porras JR, Gómez-Alonso A.
    Ann Vasc Surg. 2010 Jul;24(5):690.e9-12.
  • Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
    Pérez-Andreu V, Roldán V, López-Fernández MF, Antón AI, Alberca I, Corral J, Montes R, García-Barberá N, Ferrando F, Vicente V, González-Conejero R.
    J Thromb Haemost. 2010 May;8(5):1012-7.
  • Liposomal cytarabine is effective and tolerable in the treatment of CNS relapse of acute lymphoblastic leukemia (ALL) and very aggressive lymphoma.
    Goekbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernandez-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera JM, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D.
    Haematologica. 2010 Oct 15.
  • Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    García JL, Pérez-Caro M, Gomez-Moreta JA, González F, Ortiz J, Blanco O, Sancho M, Hernandez-Rivas JM, González-Sarmiento R, Sánchez-Martin M.
    BMC Cancer. 2010 Aug 24;10:454.
  • Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
    Matarraz S, López A, Barrena S, Fernández C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sánchez ML, Bárcena P, Hernández-Rivas JM, Salvador C, Fernandez-Mosteirín N, Giralt M, Perdiguer L, Laranjeira P, Paiva A, Orfao A.
    Cytometry B Clin Cytom. 2010 May;78(3):154-68.
  • Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
    Espinet B, Salaverria I, Beà S, Ruiz-Xivillé N, Balagué O, Salido M, Costa D, Carreras J, Rodríguez-Vicente AE, Luís García J, Hernández-Rivas JM, Calasanz MJ, Siebert R, Ferrer A, Salar A, Carrió A, Polo N, García-Marco JA, Domingo A, González-Barca E, Romagosa V, Marugán I, López-Guillermo A, Millá F, Luís Mate J, Luño E, Sanzo C, Collado R, Oliver I, Monzó S, Palacín A, González T, Sant F, Salinas R, Ardanaz MT, Font L, Escoda L, Florensa L, Serrano S, Campo E, Solé F.
    Genes Chromosomes Cancer. 2010 May;49(5):439-51.
  • Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA.
    Haematologica. 2010 Mar; 95(3):424-31.
  • Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV.
    Cancer Treat Rev. 2010 May; 36 Suppl 2:S24-32. Review.
  • Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms.
    Sebastián E, Martín J, McDonald GB, Flores T, Rodríguez A, Blanco A, Vazquez L, de Fuentes I, Caballero MD.
    Bone Marrow Transplant. 2010 Jun 28. [Epub ahead of print]
  • Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.
    Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vázquez L, Arranz R, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D; GELTAMO Group.
    Haematologica. 2010 Jul;95(7):1176-82.
  • Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
    Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL.
    Eur J Haematol. 2010 Oct;85(4):321-8.
  • Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
    Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, Díaz-Mediavilla J, Bustelos R, Fernández-Aceñero MJ, Cabrera JR; Multi-institutional Retrospective Study on the use of rituximab in refractory AIHA.
    Ann Hematol. 2010 Nov;89(11):1073-80
  • Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
    Ferrá C, Sanz J, de la Cámara R, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado I, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM; GETH (Grupo Español de Trasplante Hematopoyético) and PETHEMA (Programa Español de Tratamiento en Hematología), Spanish Society of Hematology.
    Biol Blood Marrow Transplant. 2010 Jul;16(7):957-66.
  • Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
    Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, Chiappella A, Briones J, Petrini M, Barbato A, Kayitalire L, Federico M.
    Ann Oncol. 2010 Jul;21(7):1492-9.
  • The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report on 3248 Cases from the International MILE Study Group. Haferlach T, Kohlmann A, Wieczorek L, Basso G, te Kronnie G, Béné MC, de Vos J, Macintyre E, Hernández JM, Hofmann WK, Mills KI, Gilkes AF, Chiaretti S, Downing JR, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Koay ES, Papenhausen PR, Liu WM, Xiang P, Williams PM, Foà R.
    J Clin Oncol 2010; 28: 2529-37.
  • High-Resolution Genome-Wide Analysis of Chromosomal Alterations in Elastofibroma. García JL, Ortiz Rodríguez-Parets J, Valero JM, Gómez Muñoz MA, Benito R, Hernández JM, Bullón A.
    Virchows Arch. 2010; 456: 681-7.
  • Outcome after relapse of acute lymphoblastic leukemia (ALL) in adult patients included in four consecutive risk-adapted trials from the PETHEMA Study Group. Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, Del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; for the Programa Español de Tratamiento en Hematologia (PETHEMA) Group. Haematologica 2010; 95: 589-96.
  • Reversion of epigenetically-mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA.
    Blood. 2010 116(14):2531-42.
  • Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
    Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MA, Valencia A, Florensa L, Sanz GF, Haase D, Solé F.
    Leukemia. 2010 Sep 30. [Epub ahead of print]